{"gene":"MZF1","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":1994,"finding":"MZF1 contains two independent DNA-binding domains (zinc fingers 1–4 and zinc fingers 5–13), each of which binds distinct but G-rich consensus sequences (1–4: 5'-AGTGGGGA-3'; 5–13: 5'-CGGGnGAGGGGGAA-3') as determined by affinity selection from degenerate oligonucleotide libraries followed by gel-shift assays with purified recombinant protein.","method":"Recombinant protein purification, SELEX (gel shift + PCR amplification), electrophoretic mobility shift assay (EMSA)","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified recombinant domains, SELEX-based site selection, independently validated by EMSA; foundational mechanistic paper replicated broadly","pmids":["8114711"],"is_preprint":false},{"year":1995,"finding":"MZF1 functions as a bifunctional transcriptional regulator: it represses transcription in non-hematopoietic cell lines (NIH 3T3, 293) and activates transcription in hematopoietic cell lines (K562, Jurkat) when fused to the GAL4 DNA-binding domain, and it directly binds MZF1 consensus sites in the CD34 promoter to regulate CD34 expression in a cell-type-specific manner.","method":"GAL4 fusion co-transfection/CAT reporter assay, luciferase reporter assay, EMSA with recombinant MZF1 on CD34 promoter oligonucleotides, site-directed mutation of MZF1 binding sites","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (reporter assay, EMSA, mutagenesis) in one study; replicated in subsequent work","pmids":["7579328"],"is_preprint":false},{"year":1995,"finding":"Constitutive MZF1 overexpression in embryonic stem cells inhibits hematopoietic commitment and erythromyeloid colony formation, and suppresses CD34 and c-myb promoter activity by directly binding MZF1 consensus sites in their 5'-flanking regions.","method":"Retroviral/constitutive transfection into embryonic stem cells, CAT reporter assay, EMSA with recombinant MZF1 on CD34 and c-myb promoters","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — combined in vitro binding assay, promoter reporter, and functional ES cell differentiation readout; replicated across multiple constructs","pmids":["7565760"],"is_preprint":false},{"year":1995,"finding":"Retroviral overexpression of MZF1 in NIH 3T3 fibroblasts causes loss of contact inhibition, loss of substrate dependence, accelerated cell cycling, and aggressive tumor formation in athymic mice, demonstrating oncogenic activity when MZF1 is aberrantly expressed.","method":"Retroviral transduction of NIH 3T3 cells, soft-agar/anchorage-independence assay, xenograft tumor formation in athymic mice","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean gain-of-function with multiple cellular readouts plus in vivo tumor assay; replicated in concept by subsequent studies","pmids":["7627970"],"is_preprint":false},{"year":1996,"finding":"Retroviral overexpression of MZF1 in IL-3-dependent FDCP.1 cells inhibits apoptosis upon IL-3 withdrawal and confers tumorigenic potential (tumor formation in congenic mice), indicating MZF1 promotes cell survival.","method":"Retroviral transduction, apoptosis assay upon cytokine withdrawal, syngeneic tumor formation assay","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean gain-of-function in two functional assays (apoptosis and in vivo tumor formation), single lab","pmids":["8667641"],"is_preprint":false},{"year":1998,"finding":"MZF1 overexpression in HL-60 cells delays retinoic acid-induced differentiation and apoptosis and is associated with sustained Bcl-2 expression, suggesting MZF1 promotes cell proliferation and survival partly through Bcl-2.","method":"Retroviral transduction of HL-60 cells, cell-cycle analysis, morphologic differentiation scoring, TUNEL/DNA fragmentation assay, Western blot for Bcl-2, surface marker analysis","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal readouts in a defined cellular model, single lab","pmids":["9593266"],"is_preprint":false},{"year":2000,"finding":"The SCAN box (LeR domain) present in the MZF1B isoform mediates protein–protein interactions: it is required for heterodimerization with the novel SCAN-related protein RAZ1 (identified by bone marrow cDNA library screen) and for MZF1B homodimerization, as demonstrated by co-immunoprecipitation and yeast two-hybrid analyses.","method":"Bone marrow cDNA library two-hybrid screen, co-immunoprecipitation, yeast two-hybrid with truncation constructs, in vitro self-association assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reciprocal co-IP plus yeast two-hybrid plus domain-mapping truncations; multiple orthogonal methods in one study","pmids":["10777584"],"is_preprint":false},{"year":2001,"finding":"Targeted inactivation of Mzf1 in mice produces lethal myeloid neoplasias (chloroma-like infiltrations of the liver) and markedly increases autonomous hematopoietic progenitor proliferation and long-term hematopoiesis, establishing Mzf1 as a tumor/growth suppressor in the hematopoietic compartment.","method":"Gene targeting (Mzf1 knockout mice), histopathology, hematopoietic colony assays, long-term culture-initiating cell assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic knockout with defined in vivo and ex vivo phenotypic readouts; foundational study","pmids":["11445537"],"is_preprint":false},{"year":2005,"finding":"MZF1 binds the GA-rich core of the human N-cadherin promoter (EMSA with osteoblast nuclear extracts, competition and supershift) and, together with Sp1, activates N-cadherin transcription in osteoblasts; Sp1 and MZF1 overexpression increases N-cadherin mRNA and protein.","method":"EMSA (including competition and supershift), deletion/mutation promoter-reporter analysis, co-transfection overexpression, RT-PCR","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA with supershift, promoter-reporter with mutation, and expression analysis, single lab","pmids":["15541732"],"is_preprint":false},{"year":2005,"finding":"NF-Y bound at CCAAT motifs in the ERV-9 LTR enhancer recruits MZF1 (and GATA-2) through protein–protein interactions to assemble an active enhancer complex (NF-Y/MZF1/GATA-2); NF-Y binding stabilizes MZF1 binding to neighboring GTGGGGA sites; mutation of the CCAAT motif abolishes enhancer activity and silences downstream gene transcription.","method":"EMSA, protein–protein interaction binding hierarchy assays (pull-down), chromatin analysis (DNase I sensitivity), stable plasmid integration reporter assay with site-directed mutations in K562 cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple binding assays plus functional reporter with mutagenesis, single lab","pmids":["16105833"],"is_preprint":false},{"year":2005,"finding":"MZF1 binds PKCα promoter elements in hepatocellular carcinoma cells, and antisense MZF1 oligonucleotides reduce PKCα mRNA, DNA-binding activity at the PKCα promoter, and decrease cell proliferation, migration, and invasion, placing MZF1 upstream of PKCα expression.","method":"Antisense oligonucleotide knockdown, RT-PCR, EMSA (DNA binding to PKCα promoter), cell proliferation/migration/invasion assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — loss-of-function with multiple cellular phenotype readouts plus EMSA, single lab","pmids":["16297876"],"is_preprint":false},{"year":2005,"finding":"MZF-1 interacts with LDOC1 (a leucine-zipper protein) and enhances LDOC1-induced apoptosis; LDOC1 overexpression causes phosphatidylserine externalization and mitochondrial membrane potential loss leading to caspase-3-dependent and independent apoptosis.","method":"Co-immunoprecipitation (identification of MZF-1/LDOC1 interaction), overexpression assays, flow cytometry (apoptosis), mitochondrial membrane potential assay","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP interaction plus functional overexpression assays, single lab","pmids":["15670815"],"is_preprint":false},{"year":2006,"finding":"The MZF1 SCAN domain forms a domain-swapped homodimer (Kd ~600 nM) determined by NMR spectroscopy, with the dimer interface centered on helix 3 of each monomer; GST pull-down confirmed self-association; this structure provides the molecular basis for SCAN-domain-mediated protein–protein interactions in this subfamily of zinc-finger transcription factors.","method":"NMR structure determination, GST pull-down self-association assay, tryptophan fluorescence polarization (Kd measurement), comprehensive sequence analysis","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR structure with functional validation (pull-down, Kd measurement) in single rigorous study","pmids":["16950398"],"is_preprint":false},{"year":2006,"finding":"MZF1 represses ERCC1 promoter transcription: MZF1 N-terminal zinc fingers bind a MZF1-like site in the ERCC1 promoter (EMSA), MZF1 overexpression represses ERCC1 promoter-CAT activity, and cisplatin treatment decreases MZF1 mRNA, suggesting MZF1 normally represses ERCC1 and its loss upon cisplatin exposure allows ERCC1 upregulation.","method":"EMSA with MZF1 ZN1-4 consensus oligonucleotides, CAT reporter co-transfection assay, qPCR","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA plus reporter assay with overexpression, single lab","pmids":["16426580"],"is_preprint":false},{"year":2007,"finding":"MZF1 and Sp1/Sp3 bind the proximal PADI1 promoter in vivo (ChIP assay), and siRNA knockdown of MZF1 reduces PADI1 expression in keratinocytes; mutation of MZF1- or Sp1-binding sites markedly reduces PADI1 promoter activity, establishing MZF1 as a direct transcriptional activator of PADI1.","method":"Chromatin immunoprecipitation (ChIP), luciferase reporter assay with deletion/mutation constructs, siRNA knockdown, qRT-PCR","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (ChIP, reporter mutagenesis, siRNA KD) in one study","pmids":["17851584"],"is_preprint":false},{"year":2009,"finding":"MZF-1 binds a cis-element at -785/-745 in the FGF-2 promoter (identified by promoter deletion screening) and mediates apomorphine-stimulated FGF-2 transcription in astrocytes; MZF-1 plasmid overexpression increases FGF-2 protein in HeLa cells and primary astrocytes, while MZF-1-specific siRNA reduces FGF-2 promoter activity.","method":"Promoter deletion/reporter assay, MZF-1 overexpression and siRNA knockdown, FGF-2 protein measurement","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with reporter and protein readouts, single lab","pmids":["19196427"],"is_preprint":false},{"year":2012,"finding":"MZF1 binds the cis-element 'TGGGGA' in the p55PIK (PI3K regulatory subunit) promoter (ChIP assay), and MZF1 overexpression increases while MZF1 silencing decreases p55PIK promoter activity, p55PIK expression, and colorectal cancer cell proliferation.","method":"ChIP assay, promoter-luciferase reporter assay, MZF1 overexpression and siRNA knockdown, cell proliferation assay","journal":"BioMed research international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter plus bidirectional modulation, single lab","pmids":["23509792"],"is_preprint":false},{"year":2014,"finding":"MZF1 acts as a transcriptional activator of the ferroportin (FPN) gene; reduced MZF1 expression in prostate tumors leads to decreased FPN, increased intracellular iron retention, and enhanced tumor cell growth. AP4 and c-Myb jointly activate MZF1 transcription, while miR-492 directly binds the MZF1 3'UTR to suppress MZF1 expression.","method":"MZF1 knockdown/overexpression, FPN promoter-reporter assay, iron assay, cell growth assay, miR-492 3'UTR reporter assay, quantitative RT-PCR/Western blot","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional modulation with multiple functional readouts, single lab","pmids":["25284586"],"is_preprint":false},{"year":2014,"finding":"Tumor-derived osteopontin (OPN) induces integrin-dependent MZF1 expression in mesenchymal stem cells, which is required for TGF-β1 production and MSC-to-cancer-associated-fibroblast (CAF) transformation; MZF1 knockdown abolishes OPN-induced TGF-β1 expression and CAF phenotype acquisition.","method":"In vitro MSC/cancer cell co-culture, OPN treatment, siRNA knockdown of MZF1, TGF-β1 ELISA, CAF marker analysis, xenotransplant mouse model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined molecular pathway and in vivo validation, single lab","pmids":["25531323"],"is_preprint":false},{"year":2014,"finding":"Wild-type LKB1 loss increases MZF1 expression, and MZF1 directly transcriptionally upregulates c-MYC; the MZF1/c-MYC axis drives soft-agar growth, migration and invasion in lung adenocarcinoma cells; MYC inhibitors suppress LKB1-loss-induced invasiveness.","method":"LKB1 knockdown/overexpression, MZF1 promoter-reporter assay, ChIP, soft-agar colony formation, migration/invasion assays, MYC inhibitor treatment","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter plus functional cellular assays with pharmacologic validation, single lab","pmids":["24793789"],"is_preprint":false},{"year":2014,"finding":"MZF1 binds and transactivates the FOXM1 promoter via the MZF1/NKX2-1 axis in HPV E6-positive cancer cells; E6-mediated upregulation of NKX2-1 induces MZF1, which drives FOXM1 expression and consequent Wnt/β-catenin activation, soft-agar growth, invasiveness, and stemness.","method":"siRNA knockdown, luciferase reporter assay, nude mouse metastasis model, FOXM1 inhibitor treatment, ChIP","journal":"Neoplasia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter, ChIP, and in vivo data, single lab","pmids":["25425970"],"is_preprint":false},{"year":2015,"finding":"MZF1 and Ik-1 bind specific sites in the IGF-IR gene promoter (ChIP assay), suppress IGF-IR promoter activity (luciferase assay), and forced MZF1 expression in NPM-ALK+ T-cell lymphoma cells decreases IGF-IR mRNA and protein, phospho-IGF-IR, IRS-1, AKT and NPM-ALK phosphorylation, and reduces cell viability, proliferation, migration, and anchorage-independent growth.","method":"ChIP assay, luciferase reporter assay, forced MZF1 expression, Western blot for downstream signaling, cell viability/proliferation/migration/colony assays","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, reporter, and multiple functional readouts, single lab","pmids":["25884514"],"is_preprint":false},{"year":2015,"finding":"MZF1 directly binds and activates the CTGF (CCN2) and NOV (CCN3) gene promoters in hematopoietic cells; calcitriol and vitamin A upregulate MZF1, which in turn induces CTGF and NOV expression; MZF1 shRNA knockdown reduces CTGF and NOV levels.","method":"MZF1-promoter interaction assay, MZF1 overexpression/knockdown, RT-PCR/Western blot, calcitriol/vitamin A stimulation","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — bidirectional modulation with protein-promoter interaction assays, single lab","pmids":["25899830"],"is_preprint":false},{"year":2015,"finding":"MZF1 directly binds the SMAD4 core promoter and stimulates SMAD4 transcriptional activity; MZF1 expression promotes SMAD4 levels and suppresses migration of gastric adenocarcinoma cells.","method":"Promoter-reporter assay, EMSA, MZF1 overexpression, migration assay","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — EMSA, reporter, and functional migration readout, single lab","pmids":["27922669"],"is_preprint":false},{"year":2015,"finding":"MZF1 directly binds the GAPDH promoter and upregulation of MZF1 by calcitriol induces GAPDH expression in HS-5 stromal fibroblasts; shRNA knockdown of MZF1 reduces GAPDH expression.","method":"Promoter binding assay, MZF1 knockdown (shRNA), calcitriol stimulation, Western blot/RT-PCR","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — bidirectional modulation with promoter binding evidence, single lab","pmids":["25065746"],"is_preprint":false},{"year":2015,"finding":"MZF1 forms a direct physical complex with Elk-1: Elk-1 binds the N-terminal acidic region of MZF1, MZF1 binds the C-terminal region of Elk-1; the MZF1/Elk-1 heterodimer binds the PKCα promoter to activate PKCα transcription in hepatocellular carcinoma cells; disruption of MZF1/Elk-1 dimerization reduces PKCα expression, and cell proliferation, migration, invasion, and tumorigenicity.","method":"Co-immunoprecipitation, ChIP, Re-ChIP, luciferase reporter assay with DNA-binding-deficient mutants, cell functional assays","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reciprocal Co-IP, ChIP/Re-ChIP, domain-specific mutants, and multiple functional readouts in one study","pmids":["26010542"],"is_preprint":false},{"year":2016,"finding":"The acidic domain (residues 60–72) of MZF1 and the heparin-binding domain (residues 145–157) of Elk-1 constitute the heterodimerization interface; peptides from either domain block MZF1/Elk-1 complex formation, reduce PKCα promoter binding (DNA-binding activity), and decrease PKCα expression, cell migration, tumorigenicity, and EMT potential in triple-negative breast cancer cells.","method":"Peptide competition assay, co-immunoprecipitation, ChIP, luciferase reporter assay, cell migration/invasion/tumorigenicity assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-mapping peptide competition with Co-IP, ChIP, and multiple functional readouts; single lab building on prior study","pmids":["27542222"],"is_preprint":false},{"year":2016,"finding":"The MZF1 SCAN domain adopts a conformational ensemble (validated by NMR experimental data) that mediates protein–protein interactions; cancer-associated missense substitutions in the SCAN domain perturb its interaction network as revealed by integrated proteomics, RNAseq, and molecular dynamics simulations.","method":"NMR cross-validation, molecular dynamics simulations, high-throughput proteomics and RNASeq data analysis, computational network analysis","journal":"Frontiers in molecular biosciences","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — NMR-validated structural ensemble but primarily computational; no direct mutagenesis functional validation in cells","pmids":["28018905"],"is_preprint":false},{"year":2017,"finding":"MZF1 directly binds MZF1 consensus sites within the first intron (CpG-rich region) of the PRAME gene and activates PRAME transcription; DNA demethylation (5-azaC treatment) enhances MZF1 binding and further increases PRAME expression; MZF1, like PRAME, promotes colony-forming ability in melanoma cells.","method":"ChIP, luciferase reporter assay, 5-azaC treatment, EMSA, MZF1 overexpression, colony formation assay","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, reporter, and functional assay, single lab","pmids":["28634046"],"is_preprint":false},{"year":2017,"finding":"TGF-β1-activated ERK1/2 signaling induces MZF1, which binds the CK17 promoter and activates CK17 transcription; CK17 (not EMT markers) mediates acquisition of cancer stem cell properties and lymphatic metastasis in cervical cancer; ERK1/2 inhibitors block TGF-β1-induced MZF1 and CK17 upregulation.","method":"Computational binding site prediction validated by ChIP, promoter-reporter assay, ERK1/2 inhibitor treatment, siRNA knockdown, in vivo lymphatic metastasis model","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, reporter, pharmacologic inhibition, and in vivo data, single lab","pmids":["28703907"],"is_preprint":false},{"year":2018,"finding":"FTO (m6A demethylase) enhances MZF1 mRNA stability by reducing m6A methylation of MZF1 mRNA; FTO knockdown reduces MZF1 expression (whereas catalytic mutant FTO does not rescue), and MZF1 mediates FTO's pro-tumorigenic functions in lung squamous cell carcinoma.","method":"FTO knockdown/overexpression (WT and catalytic mutant), RT-PCR/Western blot for MZF1, mRNA stability assay, cell proliferation/invasion/apoptosis assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — catalytic mutant rescue experiment distinguishes enzymatic vs. scaffolding role; functional readouts; single lab","pmids":["29842885"],"is_preprint":false},{"year":2018,"finding":"CHIP/STUB1 ubiquitin ligase negatively regulates MZF1 DNA-binding activity in the nucleus; loss of nuclear CHIP in breast cancer unleashes MZF1-driven cathepsin B/L (CTSB/L) expression, promoting tumor cell invasion and matrix degradation; ectopic CHIP expression suppresses MZF1 activity and in vivo xenograft growth.","method":"Unbiased nuclear transcription factor screen, ectopic CHIP expression, CTSB/L expression analysis, in vitro invasion/matrix degradation assays, in vivo xenograft assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with in vivo validation and functional pathway delineation, single lab","pmids":["29510992"],"is_preprint":false},{"year":2018,"finding":"CK2 directly phosphorylates MZF1 at serine 27, which stabilizes MZF1 protein; stabilized MZF1 binds the N-cadherin promoter (ChIP) and activates N-cadherin transcription; MZF1 knockdown downregulates N-cadherin, reverts cancer cells from mesenchymal to epithelial morphology, and reduces motility and invasiveness.","method":"N-cadherin promoter analysis, ChIP, co-immunoprecipitation (MZF1–CK2 interaction), phosphorylation assay (serine 27), MZF1 knockdown, morphology/motility/invasion assays","journal":"Oncogenesis","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — identified writer kinase (CK2), specific phosphorylation site (S27), ChIP, and multiple orthogonal functional assays in one study","pmids":["29540671"],"is_preprint":false},{"year":2019,"finding":"The FBXO28–TRAF6 E3 ligase complex binds ERK5, promotes ERK5 K63-ubiquitination and phosphorylation; activated ERK5 drives MZF1 expression, and MZF1 directly binds the RGC-32 promoter to upregulate RGC-32, ultimately mediating sublytic C5b-9-induced mesangial cell proliferation and ECM expansion in glomerulonephritis.","method":"Western blot, co-immunoprecipitation (FBXO28–TRAF6–ERK5 complex), ubiquitination assay, MZF1 promoter-binding analysis, siRNA knockdown of each component, in vivo Thy-1 nephritis rat model","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multi-step pathway defined by Co-IP, ubiquitination assay, and siRNA knockdowns with in vivo validation, single lab","pmids":["31184423"],"is_preprint":false},{"year":2019,"finding":"MZF1 binds the TRPV1 promoter in dorsal root ganglion (DRG) neurons and regulates TRPV1 expression; DRG microinjection of MZF1 overexpression virus increases TRPV1 and induces mechanical allodynia/thermal hyperalgesia, while MZF1 siRNA reduces CCI-induced TRPV1 upregulation and alleviates neuropathic pain behaviors.","method":"DRG microinjection of rAAV5-MZF1 or MZF1 siRNA, behavioral pain assays (PWT, PWL), Western blot/immunofluorescence for TRPV1","journal":"Neural plasticity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional modulation in vivo with specific behavioral and molecular readouts, single lab","pmids":["31582966"],"is_preprint":false},{"year":2019,"finding":"MZF1 promotes HK2 and PGK1 expression to drive aerobic glycolysis in neuroblastoma. YY1 transcription factor transactivates MZF1 transcription; a 21-amino-acid peptide (MZF1-uPEP) encoded by the upstream ORF of MZF1 binds the zinc finger domain of YY1, represses YY1 transactivation, and thereby reduces MZF1, HK2, and PGK1 expression and inhibits glycolysis and tumor progression.","method":"Dual-luciferase assay, ChIP, co-immunoprecipitation, mass spectrometry, peptide pull-down assay, seahorse extracellular flux, soft agar, Matrigel invasion, nude mice xenograft","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (Co-IP, mass spec, pulldown, ChIP, reporter, in vivo) in one study; well-validated MZF1-uPEP mechanism","pmids":["32042322"],"is_preprint":false},{"year":2019,"finding":"MZF1 acts as a transcription factor for ALDH18A1 and PYCR1, promoting proline synthesis in neuroblastoma; MZF1-AS1 lncRNA binds PARP1 to facilitate its interaction with E2F1, resulting in E2F1 transactivation of MZF1 and downstream oncogenic genes; a small peptide blocking MZF1-AS1–PARP1 interaction suppresses proline synthesis and NB progression.","method":"Dual-luciferase assay, ChIP, co-immunoprecipitation, peptide/RIP pulldown, amino acid profiling, lentiviral MZF1-AS1 shRNA, in vivo tumor assays","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods; note that MZF1-AS1 itself is a non-protein lncRNA but the MZF1 protein mechanistic findings are captured here; single lab","pmids":["31592410"],"is_preprint":false},{"year":2019,"finding":"MZF1 binds the Mtor promoter at the TGGGGA cis-element near the transcription start site and down-regulates Mtor expression; a BALB mouse-specific T at the -6 position creates the consensus MZF1 binding site, explaining strain-specific differences in Mtor promoter activity; MZF1 overexpression reduces and Mzf1 knockdown increases Mtor expression in fibroblasts and plasmacytoma cells.","method":"EMSA, DNA pulldown, ChIP-PCR, luciferase reporter assay with allelic variants, MZF1 overexpression/knockdown in cell lines","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — EMSA, DNA pulldown, ChIP, reporter, and bidirectional modulation, multiple orthogonal methods in one study","pmids":["31548308"],"is_preprint":false},{"year":2020,"finding":"Linc01060 (a lncRNA from hypoxic glioma stem cell exosomes) directly interacts with MZF1 protein and enhances its stability; Linc01060 facilitates nuclear translocation of MZF1 and promotes MZF1-mediated c-Myc transcriptional activity; c-Myc then increases HIF1α accumulation post-transcriptionally, which feeds back to activate Linc01060 transcription.","method":"RNA immunoprecipitation (RIP), co-immunoprecipitation, nuclear fractionation, dual-luciferase, ChIP, overexpression/knockdown assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIP/Co-IP and nuclear fractionation with reporter and ChIP; single lab; note this is about the MZF1 protein mechanism","pmids":["33158815"],"is_preprint":false},{"year":2021,"finding":"MZF1 recruits chromodomain helicase DNA binding protein 7 (CHD7) to the p16INK4A (CDKN2A) promoter to mediate oncogenic Ras-induced p16INK4A transcription and cellular senescence in primary human cells; MZF1 expression is induced by oncogenic Ras through the c-Jun and Ets1 transcription factors activated by the Ras-Raf-1-MEK-ERK signaling cascade.","method":"ChIP, co-immunoprecipitation (MZF1–CHD7), MZF1 knockdown/overexpression, p16INK4A promoter-reporter assay, senescence assays (SA-β-gal), oncogenic Ras expression, pathway inhibitor treatments","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — Co-IP identifying CHD7 as MZF1 cofactor, ChIP showing recruitment to p16INK4A promoter, pathway epistasis with inhibitors, and functional senescence readout; multiple orthogonal methods","pmids":["34773072"],"is_preprint":false},{"year":2021,"finding":"GSK3β mediates ubiquitination and degradation of the m6A demethylase FTO, thereby increasing m6A methylation of MZF1 mRNA and reducing MZF1 expression, which in turn decreases c-Myc expression and suppresses colorectal cancer cell proliferation; overexpressing c-Myc reverses GSK3β-mediated tumor suppression in vivo.","method":"Ubiquitination assay, m6A MeRIP, protein stability assay, transfection of overexpression/interference plasmids, in vivo tumor model","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay plus m6A profiling plus in vivo rescue, single lab","pmids":["33533172"],"is_preprint":false},{"year":2021,"finding":"Irradiation increases MZF1 expression in alveolar epithelial cells; MZF1 binds the miR-541-5p primary precursor promoter and represses miR-541-5p transcription; reduced miR-541-5p releases its target Slug, promoting EMT and radiation-induced pulmonary fibrosis; ectopic miR-541-5p expression mitigates RIPF in mice.","method":"Luciferase reporter assay, ChIP (MZF1 binding to miR-541-5p promoter), overexpression/knockdown of MZF1 and miR-541-5p, in vivo RIPF mouse model, EMT marker analysis","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, reporter, and in vivo data, single lab","pmids":["34768749"],"is_preprint":false},{"year":2022,"finding":"MZF1 cooperates with SETD8 (lysine methyltransferase) to regulate WNT5A promoter transcription in glomerular endothelial cells: MZF1 and SETD8 co-occupy the WNT5A promoter (ChIP), physically interact (Co-IP), and under high-glucose conditions MZF1 and SETD8 mutually inhibit each other while together activating WNT5A, leading to NF-κB pathway activation and endothelial inflammation.","method":"ChIP, co-immunoprecipitation, dual-luciferase assay, siRNA/overexpression of MZF1 and SETD8, in vivo DN rat model, Western blot for p-p65/inflammatory markers","journal":"Cellular & molecular biology letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ChIP, reporter, bidirectional modulation, and in vivo model; single lab","pmids":["35350980"],"is_preprint":false},{"year":2022,"finding":"MZF1 binds the SIRT6 promoter and regulates SIRT6 expression; SIRT6 inhibits the Warburg effect by regulating glycolysis genes (SLC2A2, SLC2A4, PKM2); the MZF1-SIRT6 complex is demonstrated by ChIP-qPCR; mitoAMPK acts upstream of the MZF1-SIRT6 axis.","method":"ChIP-qPCR (MZF1–SIRT6 promoter interaction), Western blot, qPCR, CCK-8, immunohistochemistry, glycolysis gene expression analysis","journal":"Journal of cellular and molecular medicine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single ChIP-qPCR experiment with limited mechanistic follow-up, single lab","pmids":["39224032"],"is_preprint":false},{"year":2023,"finding":"MZF1 binds and represses the SLC1A5 (ASCT2) promoter; the lncRNA SLC1A5-AS directly binds MZF1 protein (biotin-labeled probe pulldown), sequestering it from the promoter and thereby de-repressing ASCT2 to enhance glutamine uptake and HCC progression.","method":"Biotin-labeled RNA probe pulldown/Western blot (SLC1A5-AS–MZF1 interaction), ChIP, dual-luciferase reporter assay, overexpression/knockdown, glutamine uptake assay, in vitro and in vivo functional assays","journal":"Discovery medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA pulldown, ChIP, and reporter with functional readouts; single lab; note the lncRNA mechanism is supporting context, the MZF1 protein binding/repression is directly demonstrated","pmids":["38058065"],"is_preprint":false},{"year":2023,"finding":"UHRF1/DNMT1-mediated hypermethylation of an intragenic CpG island in PRSS3 prevents MZF1 binding to regulate PRSS3 isoform transcription; when iCpGI is demethylated (by diallyl trisulfide + 5-azaC), MZF1 specifically binds to upregulate tumor-suppressive PRSS3-V3 expression.","method":"DNMT1/UHRF1 complex assay, bisulfite sequencing, MZF1 ChIP on iCpGI, luciferase reporter assay, pharmacologic demethylation, isoform-specific RT-PCR","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, reporter, and epigenetic modulation with isoform-specific readouts; single lab","pmids":["37250150"],"is_preprint":false},{"year":2023,"finding":"MZF1 accelerates PD-L1 ubiquitination by binding to the CDK4 activation site; CDK4 directly binds MZF1 (co-immunoprecipitation) leading to increased MZF1 expression; ectopic MZF1 expression impairs T-cell recruitment into tumors and confers resistance to anti-PD-L1 immunotherapy in hepatocellular carcinoma.","method":"Co-immunoprecipitation (CDK4–MZF1 complex), ubiquitination assay, proteome analysis, protein degradation assays, orthotopic and hydrodynamic HCC mouse models, T-cell infiltration analysis","journal":"JHEP reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination assay, and in vivo models with immune readout; single lab","pmids":["38074509"],"is_preprint":false},{"year":2023,"finding":"MZF1 is the transcription factor that activates CLDND1 expression; the miR-199a-3p/FTO/MZF1 axis regulates NSCLC: miR-199a-3p suppresses FTO, enhancing m6A modification of MZF1 mRNA (confirmed by MeRIP and CLIP) and reducing MZF1, which decreases CLDND1 and inhibits NSCLC cell malignancy.","method":"Methylated RNA immunoprecipitation (MeRIP), CLIP (photoactivatable ribonucleoside-enhanced CLIP for FTO–MZF1 mRNA binding), dual-luciferase assay (miR-199a-3p targeting FTO; MZF1 activating CLDND1), MZF1 knockdown, cell proliferation/invasion/migration/apoptosis assays","journal":"Molecular medicine reports","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — MeRIP and CLIP for post-transcriptional m6A mechanism, reporter for CLDND1 transcriptional activation, multiple orthogonal methods; single lab","pmids":["41201047"],"is_preprint":false},{"year":2025,"finding":"MZF1 forms discrete intranuclear oligomeric structures termed MZF1 nuclear bodies (MZF1-NBs), distinct from but associated with PML-NBs; MZF1 is SUMOylated at SUMO1 in PC-3 cells, enabling interaction with SUMO-interaction motif (SIM)-containing proteins; interactome analysis of MZF1-NBs identified cofactors involved in stress response (TPR, UBAP2L), protein folding (CALR, ANKRD40), post-translational modification (TRIM33, CAMK2D, CAMK2G), and RNA binding (ALURBP, CPSF5).","method":"Live-cell imaging (nuclear body morphology), proteomic interactome analysis, co-immunoprecipitation, SUMO1 modification assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct subcellular localization and proteomics-based interactome, single lab, single study with limited functional validation","pmids":["39954358"],"is_preprint":false},{"year":2025,"finding":"NSUN2-mediated m5C modification of MZF1 mRNA is required for its recognition and stabilization by the m5C reader protein ALYREF; ALYREF knockdown reduces MZF1 and HTRA1 expression, alleviates myocardial hypertrophy, fibrosis, and atrial fibrillation inducibility in an ISO-induced heart failure mouse model.","method":"MeRIP-qPCR for m5C on MZF1 mRNA, RIP-qPCR (ALYREF–MZF1 mRNA interaction), actinomycin D mRNA stability assay, ChIP (MZF1 on HTRA1 promoter), dual-luciferase reporter, in vivo HF mouse model with ALYREF knockdown","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — m5C MeRIP, RIP, mRNA stability assay, ChIP, and in vivo data; single lab","pmids":["42249105"],"is_preprint":false}],"current_model":"MZF1 is a Krüppel-family C2H2 zinc finger transcription factor with two independent DNA-binding domains that recognize G-rich consensus sequences; it functions as a bifunctional regulator—activating transcription in hematopoietic cells and repressing it in non-hematopoietic contexts—and acts either as a tumor suppressor (driving p16INK4A/senescence, ferroportin-mediated iron egress) or oncogene (driving c-Myc, PKCα, cathepsin B/L, and glycolytic genes) depending on cellular context; its activity is post-translationally regulated by CK2-mediated phosphorylation at serine 27 (stabilization), CHIP ubiquitin-ligase-mediated repression, and SUMO1 modification, while its mRNA stability is controlled by FTO-mediated m6A demethylation and NSUN2/ALYREF-mediated m5C stabilization; its SCAN domain forms a domain-swapped homodimer and mediates heterodimerization with partners including RAZ1, Elk-1, CHD7, YY1, SETD8, and CDK4, enabling context-dependent transcriptional programs across hematopoiesis, cancer invasion/EMT, glycolysis, senescence, and neuropathic pain."},"narrative":{"mechanistic_narrative":"MZF1 (myeloid zinc finger 1) is a Krüppel-family C2H2 zinc finger transcription factor that uses two independent DNA-binding domains—zinc fingers 1–4 and 5–13, each recognizing a distinct G-rich consensus—to regulate target genes from G-rich promoter elements [PMID:8114711]. It functions as a context-dependent bifunctional regulator, repressing transcription in non-hematopoietic cells while activating it in hematopoietic cells, and it directly controls hematopoietic differentiation genes including CD34 and c-myb [PMID:7579328, PMID:7565760]. Genetic loss of Mzf1 in mice causes lethal myeloid neoplasia and autonomous progenitor proliferation, establishing it as a hematopoietic growth/tumor suppressor, whereas aberrant overexpression confers anchorage-independent growth and tumorigenicity in fibroblasts and survival signaling in myeloid cells [PMID:7627970, PMID:11445537]. Across cancers MZF1 directly transactivates a broad set of pro-tumorigenic targets—c-MYC, PKCα, FOXM1, p55PIK, and cathepsin B/L—to drive proliferation, invasion, EMT, and matrix degradation [PMID:24793789, PMID:26010542, PMID:25425970, PMID:29510992], yet it also acts as a tumor suppressor by activating ferroportin and SMAD4 and by repressing IGF-IR, illustrating strict context dependence [PMID:25284586, PMID:27922669, PMID:25884514]. Its protein–protein interactions are organized by an N-terminal SCAN domain that forms a domain-swapped homodimer and supports heterodimerization with partners such as RAZ1, and by a separate acidic region that mediates direct heterodimerization with Elk-1 to assemble DNA-binding transcription complexes on the PKCα promoter [PMID:16950398, PMID:10777584, PMID:26010542]. MZF1 also nucleates cofactor complexes with CHD7 to drive oncogenic-Ras-induced p16INK4A transcription and senescence, and with SETD8 on the WNT5A promoter [PMID:34773072, PMID:35350980]. Its activity and abundance are tightly post-translationally controlled: CK2 phosphorylates MZF1 at serine 27 to stabilize it and promote N-cadherin-driven EMT, the CHIP/STUB1 ubiquitin ligase represses its nuclear DNA-binding activity, and SUMO1 modification organizes MZF1 into intranuclear nuclear bodies (MZF1-NBs) linked to a stress-response and RNA-binding interactome [PMID:29540671, PMID:29510992, PMID:39954358]. MZF1 mRNA itself is a node of RNA modification control, being stabilized by FTO-mediated m6A demethylation and by NSUN2/ALYREF-mediated m5C reading [PMID:29842885, PMID:33533172, PMID:42249105]. Beyond cancer, MZF1 transcriptionally regulates TRPV1 in dorsal root ganglion neurons to drive neuropathic pain and engages glycolytic and proline-synthesis programs (HK2, PGK1, ALDH18A1, PYCR1) in neuroblastoma, where a uORF-encoded micropeptide modulates its upstream activator YY1 [PMID:31582966, PMID:32042322, PMID:31592410].","teleology":[{"year":1994,"claim":"Defining the DNA-recognition logic of MZF1 was the first mechanistic question: the work established that MZF1 has two independent zinc-finger DNA-binding modules each recognizing a distinct G-rich consensus, explaining how one factor can engage diverse promoters.","evidence":"SELEX site selection and EMSA with purified recombinant zinc-finger domains","pmids":["8114711"],"confidence":"High","gaps":["Did not establish which target genes the two consensus motifs map to in vivo","No structural model of finger-DNA contacts"]},{"year":1995,"claim":"These studies resolved whether MZF1 activates or represses, showing it is bifunctional in a cell-type-dependent manner and directly controls hematopoietic genes CD34 and c-myb, framing MZF1 as a regulator of myeloid differentiation.","evidence":"GAL4-fusion reporter assays, EMSA, promoter mutagenesis, and ES-cell differentiation readouts in hematopoietic vs non-hematopoietic lines","pmids":["7579328","7565760"],"confidence":"High","gaps":["Molecular basis of the activator-vs-repressor switch (cofactor identity) not defined","Did not identify cell-type-specific partners driving the switch"]},{"year":1995,"claim":"Gain-of-function experiments addressed whether dysregulated MZF1 is oncogenic, demonstrating that aberrant overexpression transforms fibroblasts and promotes tumor formation and that it blocks IL-3-withdrawal apoptosis, linking MZF1 to proliferation and survival.","evidence":"Retroviral overexpression with anchorage-independence, xenograft/syngeneic tumor formation, and cytokine-withdrawal apoptosis assays","pmids":["7627970","8667641","9593266"],"confidence":"Medium","gaps":["Transforming target genes not identified in these models","Survival mechanism beyond association with Bcl-2 not delineated"]},{"year":2001,"claim":"A definitive loss-of-function test asked whether endogenous Mzf1 restrains hematopoietic growth in vivo, showing knockout mice develop lethal myeloid neoplasia and autonomous progenitor proliferation—establishing MZF1 as a hematopoietic tumor/growth suppressor in apparent paradox with its oncogenic overexpression phenotypes.","evidence":"Mzf1 knockout mice with histopathology and hematopoietic colony/LTC-IC assays","pmids":["11445537"],"confidence":"High","gaps":["Direct target genes mediating the suppressor phenotype not identified","Reconciliation of suppressor vs oncogene roles at molecular level unresolved"]},{"year":2000,"claim":"To explain how MZF1 forms higher-order complexes, the SCAN/LeR domain was identified as the protein-interaction module mediating homodimerization and heterodimerization with the SCAN-related partner RAZ1.","evidence":"Bone-marrow two-hybrid screen, co-IP, and yeast two-hybrid truncation mapping","pmids":["10777584"],"confidence":"High","gaps":["Functional consequence of RAZ1 heterodimerization on transcription not tested","Full repertoire of SCAN partners unknown"]},{"year":2006,"claim":"Structural work answered how the SCAN domain mediates dimerization, revealing a domain-swapped homodimer with a helix-3 interface and a measurable affinity, providing the molecular basis for SCAN-mediated interactions.","evidence":"NMR structure determination, GST pull-down, and Kd measurement by fluorescence polarization","pmids":["16950398"],"confidence":"High","gaps":["Structure of heterodimeric SCAN complexes not solved","No structure of full-length MZF1 with DNA"]},{"year":2005,"claim":"Identification of direct promoter targets in non-hematopoietic contexts (N-cadherin, ERV-9 LTR, PKCα, ERCC1) and partners (NF-Y, GATA-2, Sp1, LDOC1) showed MZF1 assembles cell-type-specific enhancer complexes and can both activate and repress distinct targets.","evidence":"EMSA/supershift, promoter-reporter mutagenesis, antisense/co-transfection, and co-IP across osteoblast, K562, hepatoma, and apoptosis models","pmids":["15541732","16105833","16297876","16426580","15670815"],"confidence":"Medium","gaps":["Whether MZF1 directly recruits the named partners or co-occupies independently is often not separated","In vivo relevance of individual targets to physiology not established"]},{"year":2014,"claim":"A large body of cancer studies mapped MZF1 into specific oncogenic and tumor-suppressive transcriptional circuits, defining context-dependent direct targets (c-MYC, FOXM1, p55PIK, ferroportin, SMAD4, IGF-IR, PRAME, CK17) and upstream activators (LKB1 loss, OPN/integrin, NKX2-1, TGF-β1/ERK).","evidence":"ChIP, promoter-reporter assays, bidirectional knockdown/overexpression, pharmacologic pathway inhibition, and xenograft/metastasis models across multiple tumor types","pmids":["24793789","25425970","23509792","25284586","27922669","25884514","28634046","28703907","25531323","25899830"],"confidence":"Medium","gaps":["What determines oncogene vs suppressor target selection in a given tissue is not resolved","Most targets are demonstrated in a single lab/model"]},{"year":2025,"claim":"A second mechanistic layer was opened by showing MZF1 is itself heavily post-translationally and post-transcriptionally regulated: CK2 phosphorylation at S27 stabilizes it, CHIP/STUB1 represses its nuclear DNA-binding, SUMO1 organizes it into MZF1 nuclear bodies, and m6A (FTO) and m5C (NSUN2/ALYREF) marks tune its mRNA stability.","evidence":"Phosphorylation/co-IP assays, ubiquitin-ligase functional screens, SUMOylation and live-cell imaging with interactome proteomics, and MeRIP/RIP/CLIP/mRNA-stability assays with in vivo models","pmids":["29540671","29510992","48","39954358","29842885","33533172","41201047","42249105"],"confidence":"Medium","gaps":["Functional output of MZF1-NBs and SUMOylation not mechanistically tied to transcriptional programs","How these inputs are integrated to set net MZF1 activity is undefined"]},{"year":2021,"claim":"Cofactor-based mechanisms clarified how MZF1 controls senescence and metabolic programs: it recruits CHD7 to the p16INK4A promoter to enact oncogenic-Ras senescence, cooperates with SETD8 on WNT5A, and drives glycolytic/proline-synthesis genes regulated by a uORF-encoded micropeptide acting on its activator YY1.","evidence":"Co-IP cofactor identification, ChIP, senescence assays, Seahorse/amino-acid profiling, peptide pull-down, and xenografts","pmids":["34773072","35350980","32042322","31592410"],"confidence":"High","gaps":["Generality of CHD7/SETD8 recruitment across other targets unknown","How chromatin cofactor choice is governed is unresolved"]},{"year":2019,"claim":"MZF1 was shown to operate in non-cancer tissue contexts—neuropathic pain via TRPV1 in DRG neurons, glomerular inflammation/fibrosis via RGC-32 and WNT5A, mTOR regulation, and cardiac remodeling via HTRA1—broadening its physiological reach beyond hematopoiesis and tumors.","evidence":"DRG microinjection with behavioral assays, ChIP/reporter assays, EMSA/DNA pulldown for allelic Mtor sites, and in vivo nephritis, fibrosis, and heart-failure models","pmids":["31582966","31184423","31548308","42249105"],"confidence":"Medium","gaps":["Tissue-specific cofactors enabling these distinct programs not identified","Most physiological roles rest on single studies"]},{"year":null,"claim":"The central unresolved question is what molecular determinant switches MZF1 between tumor-suppressor and oncogene roles and selects its activator vs repressor mode on a given promoter.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking partner identity, post-translational state, and target selection","No genome-wide occupancy comparison across hematopoietic vs non-hematopoietic contexts in the corpus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,2,14,25,32,37]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,2,13,37]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[31,48]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[48]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,2,14,25,32,37]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,7,19,31,35]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[30,40,47,49]}],"complexes":["MZF1 SCAN domain-swapped homodimer","MZF1/Elk-1 heterodimer","MZF1 nuclear bodies (MZF1-NBs)"],"partners":["RAZ1","ELK-1","CHD7","SETD8","CDK4","CK2","STUB1","YY1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P28698","full_name":"Myeloid zinc finger 1","aliases":["Zinc finger and SCAN domain-containing protein 6","Zinc finger protein 42"],"length_aa":734,"mass_kda":82.1,"function":"Binds to target promoter DNA and functions as a transcription regulator. Regulates transcription from the PADI1 and CDH2 promoter. May be one regulator of transcriptional events during hemopoietic development","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P28698/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MZF1","classification":"Not Classified","n_dependent_lines":285,"n_total_lines":1208,"dependency_fraction":0.2359271523178808},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MZF1","total_profiled":1310},"omim":[{"mim_id":"619677","title":"CLAUDIN DOMAIN-CONTAINING PROTEIN 1; CLDND1","url":"https://www.omim.org/entry/619677"},{"mim_id":"617889","title":"PYRIDINE NUCLEOTIDE-DISULPHIDE OXIDOREDUCTASE DOMAIN-CONTAINING PROTEIN 2; PYROXD2","url":"https://www.omim.org/entry/617889"},{"mim_id":"615321","title":"CHLORIDE INTRACELLULAR CHANNEL 6; CLIC6","url":"https://www.omim.org/entry/615321"},{"mim_id":"614336","title":"PRESEQUENCE TRANSLOCASE-ASSOCIATED MOTOR 16; PAM16","url":"https://www.omim.org/entry/614336"},{"mim_id":"613635","title":"EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 1; EIF2AK1","url":"https://www.omim.org/entry/613635"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MZF1"},"hgnc":{"alias_symbol":["ZSCAN6","MZF1B","MZF-1","Zfp98"],"prev_symbol":["ZNF42"]},"alphafold":{"accession":"P28698","domains":[{"cath_id":"1.10.4020.10","chopping":"39-115","consensus_level":"medium","plddt":83.9545,"start":39,"end":115},{"cath_id":"3.30.160.60","chopping":"585-731","consensus_level":"medium","plddt":88.1118,"start":585,"end":731}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P28698","model_url":"https://alphafold.ebi.ac.uk/files/AF-P28698-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P28698-F1-predicted_aligned_error_v6.png","plddt_mean":65.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MZF1","jax_strain_url":"https://www.jax.org/strain/search?query=MZF1"},"sequence":{"accession":"P28698","fasta_url":"https://rest.uniprot.org/uniprotkb/P28698.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P28698/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P28698"}},"corpus_meta":[{"pmid":"29842885","id":"PMC_29842885","title":"m6A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29842885","citation_count":200,"is_preprint":false},{"pmid":"25531323","id":"PMC_25531323","title":"Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25531323","citation_count":191,"is_preprint":false},{"pmid":"8114711","id":"PMC_8114711","title":"Characterization of the DNA-binding properties of the myeloid zinc finger protein MZF1: two independent DNA-binding domains recognize two DNA consensus sequences with a common G-rich core.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8114711","citation_count":174,"is_preprint":false},{"pmid":"1860835","id":"PMC_1860835","title":"A retinoic acid-responsive human zinc finger gene, MZF-1, preferentially expressed in myeloid cells.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1860835","citation_count":167,"is_preprint":false},{"pmid":"11445537","id":"PMC_11445537","title":"Mzf1 controls cell proliferation and tumorigenesis.","date":"2001","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/11445537","citation_count":112,"is_preprint":false},{"pmid":"33158815","id":"PMC_33158815","title":"Hypoxic Glioma Stem Cell-Derived Exosomes Containing Linc01060 Promote Progression of Glioma by Regulating the MZF1/c-Myc/HIF1α Axis.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33158815","citation_count":106,"is_preprint":false},{"pmid":"7565760","id":"PMC_7565760","title":"Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7565760","citation_count":105,"is_preprint":false},{"pmid":"7579328","id":"PMC_7579328","title":"The myeloid zinc finger gene, MZF-1, regulates the CD34 promoter in vitro.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7579328","citation_count":96,"is_preprint":false},{"pmid":"8585946","id":"PMC_8585946","title":"Hematopoietic transcriptional regulation by the myeloid zinc finger gene, MZF-1.","date":"1996","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8585946","citation_count":84,"is_preprint":false},{"pmid":"1719120","id":"PMC_1719120","title":"Antisense oligonucleotides from the stage-specific myeloid zinc finger gene MZF-1 inhibit granulopoiesis in vitro.","date":"1991","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1719120","citation_count":79,"is_preprint":false},{"pmid":"24793789","id":"PMC_24793789","title":"The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24793789","citation_count":62,"is_preprint":false},{"pmid":"7627970","id":"PMC_7627970","title":"Aberrant expression of the myeloid zinc finger gene, MZF-1, is oncogenic.","date":"1995","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7627970","citation_count":60,"is_preprint":false},{"pmid":"15541732","id":"PMC_15541732","title":"Sp1/Sp3 and the myeloid zinc finger gene MZF1 regulate the human N-cadherin promoter in osteoblasts.","date":"2005","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15541732","citation_count":57,"is_preprint":false},{"pmid":"25284586","id":"PMC_25284586","title":"Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25284586","citation_count":54,"is_preprint":false},{"pmid":"16105833","id":"PMC_16105833","title":"The long terminal repeat (LTR) of ERV-9 human endogenous retrovirus binds to NF-Y in the assembly of an active LTR enhancer complex NF-Y/MZF1/GATA-2.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16105833","citation_count":50,"is_preprint":false},{"pmid":"16297876","id":"PMC_16297876","title":"PKCalpha expression regulated by Elk-1 and MZF-1 in human HCC cells.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16297876","citation_count":48,"is_preprint":false},{"pmid":"10777584","id":"PMC_10777584","title":"Identification of a novel SCAN box-related protein that interacts with MZF1B. The leucine-rich SCAN box mediates hetero- and homoprotein associations.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10777584","citation_count":46,"is_preprint":false},{"pmid":"9593266","id":"PMC_9593266","title":"The myeloid zinc finger gene (MZF-1) delays retinoic acid-induced apoptosis and differentiation in myeloid leukemia cells.","date":"1998","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9593266","citation_count":46,"is_preprint":false},{"pmid":"28703907","id":"PMC_28703907","title":"TGF-β1-induced CK17 enhances cancer stem cell-like properties rather than EMT in promoting cervical cancer metastasis via the ERK1/2-MZF1 signaling pathway.","date":"2017","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/28703907","citation_count":46,"is_preprint":false},{"pmid":"25425970","id":"PMC_25425970","title":"Up-regulation of FOXM1 by E6 oncoprotein through the MZF1/NKX2-1 axis is required for human papillomavirus-associated tumorigenesis.","date":"2014","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/25425970","citation_count":44,"is_preprint":false},{"pmid":"32042322","id":"PMC_32042322","title":"Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32042322","citation_count":42,"is_preprint":false},{"pmid":"29510992","id":"PMC_29510992","title":"Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29510992","citation_count":40,"is_preprint":false},{"pmid":"15670815","id":"PMC_15670815","title":"LDOC1, a novel MZF-1-interacting protein, induces apoptosis.","date":"2005","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15670815","citation_count":38,"is_preprint":false},{"pmid":"31592410","id":"PMC_31592410","title":"Therapeutic Targeting of MZF1-AS1/PARP1/E2F1 Axis Inhibits Proline Synthesis and Neuroblastoma Progression.","date":"2019","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/31592410","citation_count":38,"is_preprint":false},{"pmid":"23509792","id":"PMC_23509792","title":"p55PIK transcriptionally activated by MZF1 promotes colorectal cancer cell proliferation.","date":"2012","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/23509792","citation_count":38,"is_preprint":false},{"pmid":"31963147","id":"PMC_31963147","title":"Zinc Finger Transcription Factor MZF1-A Specific Regulator of Cancer Invasion.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31963147","citation_count":37,"is_preprint":false},{"pmid":"28634046","id":"PMC_28634046","title":"Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28634046","citation_count":36,"is_preprint":false},{"pmid":"33533172","id":"PMC_33533172","title":"Kinase GSK3β functions as a suppressor in colorectal carcinoma through the FTO-mediated MZF1/c-Myc axis.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33533172","citation_count":35,"is_preprint":false},{"pmid":"16426580","id":"PMC_16426580","title":"MZF1 possesses a repressively regulatory function in ERCC1 expression.","date":"2006","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16426580","citation_count":33,"is_preprint":false},{"pmid":"17851584","id":"PMC_17851584","title":"Crucial roles of MZF1 and Sp1 in the transcriptional regulation of the peptidylarginine deiminase type I gene (PADI1) in human keratinocytes.","date":"2007","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17851584","citation_count":29,"is_preprint":false},{"pmid":"19196427","id":"PMC_19196427","title":"Crucial roles of MZF-1 in the transcriptional regulation of apomorphine-induced modulation of FGF-2 expression in astrocytic cultures.","date":"2009","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19196427","citation_count":29,"is_preprint":false},{"pmid":"28018905","id":"PMC_28018905","title":"The Mutational Landscape of the Oncogenic MZF1 SCAN Domain in Cancer.","date":"2016","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/28018905","citation_count":28,"is_preprint":false},{"pmid":"8845378","id":"PMC_8845378","title":"Isolation and functional characterization of the human gene encoding the myeloid zinc finger protein MZF-1.","date":"1995","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8845378","citation_count":25,"is_preprint":false},{"pmid":"17593797","id":"PMC_17593797","title":"Suppression of tumorigenicity of human hepatocellular carcinoma cells by antisense oligonucleotide MZF-1.","date":"2007","source":"The Chinese journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17593797","citation_count":25,"is_preprint":false},{"pmid":"34768749","id":"PMC_34768749","title":"Irradiation Activates MZF1 to Inhibit miR-541-5p Expression and Promote Epithelial-Mesenchymal Transition (EMT) in Radiation-Induced Pulmonary Fibrosis (RIPF) by Upregulating Slug.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34768749","citation_count":25,"is_preprint":false},{"pmid":"8667641","id":"PMC_8667641","title":"Forced over-expression of the myeloid zinc finger gene MZF-1 inhibits apoptosis and promotes oncogenesis in interleukin-3-dependent FDCP.1 cells.","date":"1996","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8667641","citation_count":24,"is_preprint":false},{"pmid":"26010542","id":"PMC_26010542","title":"MZF-1/Elk-1 Complex Binds to Protein Kinase Cα Promoter and Is Involved in Hepatocellular Carcinoma.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26010542","citation_count":21,"is_preprint":false},{"pmid":"25884514","id":"PMC_25884514","title":"The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma.","date":"2015","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25884514","citation_count":21,"is_preprint":false},{"pmid":"29540671","id":"PMC_29540671","title":"Phosphorylation-dependent stabilization of MZF1 upregulates N-cadherin expression during protein kinase CK2-mediated epithelial-mesenchymal transition.","date":"2018","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/29540671","citation_count":20,"is_preprint":false},{"pmid":"37250150","id":"PMC_37250150","title":"UHRF1/DNMT1-MZF1 axis-modulated intragenic site-specific CpGI methylation confers divergent expression and opposing functions of PRSS3 isoforms in lung cancer.","date":"2023","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/37250150","citation_count":20,"is_preprint":false},{"pmid":"16950398","id":"PMC_16950398","title":"Structure of the SCAN domain from the tumor suppressor protein MZF1.","date":"2006","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16950398","citation_count":20,"is_preprint":false},{"pmid":"34773072","id":"PMC_34773072","title":"MZF1 mediates oncogene-induced senescence by promoting the transcription of p16INK4A.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34773072","citation_count":16,"is_preprint":false},{"pmid":"36992161","id":"PMC_36992161","title":"Design and In Silico Validation of a Novel MZF-1-Based Multi-Epitope Vaccine to Combat Metastatic Triple Negative Breast Cancer.","date":"2023","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/36992161","citation_count":16,"is_preprint":false},{"pmid":"27542222","id":"PMC_27542222","title":"MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27542222","citation_count":15,"is_preprint":false},{"pmid":"35350980","id":"PMC_35350980","title":"SETD8 cooperates with MZF1 to participate in hyperglycemia-induced endothelial inflammation via elevation of WNT5A levels in diabetic nephropathy.","date":"2022","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/35350980","citation_count":15,"is_preprint":false},{"pmid":"31184423","id":"PMC_31184423","title":"Sublytic C5b-9 induces proliferation of glomerular mesangial cells via ERK5/MZF1/RGC-32 axis activated by FBXO28-TRAF6 complex.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31184423","citation_count":15,"is_preprint":false},{"pmid":"27922669","id":"PMC_27922669","title":"Upregulation of SMAD4 by MZF1 inhibits migration of human gastric cancer cells.","date":"2016","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27922669","citation_count":15,"is_preprint":false},{"pmid":"37209940","id":"PMC_37209940","title":"Asiatic acid exhibits antimetastatic activity in human prostate cancer cells by modulating the MZF-1/Elk-1/Snail signaling axis.","date":"2023","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37209940","citation_count":12,"is_preprint":false},{"pmid":"31582966","id":"PMC_31582966","title":"MZF1 in the Dorsal Root Ganglia Contributes to the Development and Maintenance of Neuropathic Pain via Regulation of TRPV1.","date":"2019","source":"Neural plasticity","url":"https://pubmed.ncbi.nlm.nih.gov/31582966","citation_count":12,"is_preprint":false},{"pmid":"38058065","id":"PMC_38058065","title":"LncRNA SLC1A5-AS/MZF1/ASCT2 Axis Contributes to Malignant Progression of Hepatocellular Carcinoma.","date":"2023","source":"Discovery medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38058065","citation_count":11,"is_preprint":false},{"pmid":"25436607","id":"PMC_25436607","title":"Myeloid zinc finger 1 (Mzf1) differentially modulates murine cardiogenesis by interacting with an Nkx2.5 cardiac enhancer.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25436607","citation_count":11,"is_preprint":false},{"pmid":"38074509","id":"PMC_38074509","title":"MZF1 promotes tumour progression and resistance to anti-PD-L1 antibody treatment in hepatocellular carcinoma.","date":"2023","source":"JHEP reports : innovation in hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/38074509","citation_count":10,"is_preprint":false},{"pmid":"22242952","id":"PMC_22242952","title":"Expression of protein kinase C α and the MZF-1 and Elk-1 transcription factors in human breast cancer cells.","date":"2012","source":"The Chinese journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22242952","citation_count":10,"is_preprint":false},{"pmid":"31366500","id":"PMC_31366500","title":"Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERα Signaling Pathway in High-level MZF1-expressing TNBC cells.","date":"2019","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31366500","citation_count":10,"is_preprint":false},{"pmid":"31548308","id":"PMC_31548308","title":"The transcription factor MZF1 differentially regulates murine Mtor promoter variants linked to tumor susceptibility.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31548308","citation_count":10,"is_preprint":false},{"pmid":"8637224","id":"PMC_8637224","title":"The location of MZF-1 at the telomere of human chromosome 19q makes it vulnerable to degeneration in aging cells.","date":"1996","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/8637224","citation_count":10,"is_preprint":false},{"pmid":"36499054","id":"PMC_36499054","title":"Inhibition of MZF1/c-MYC Axis by Cantharidin Impairs Cell Proliferation in Glioblastoma.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36499054","citation_count":9,"is_preprint":false},{"pmid":"15893750","id":"PMC_15893750","title":"MZF-1 and DbpA interact with DNase I hypersensitive sites that correlate with expression of the human MUC1 mucin gene.","date":"2005","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15893750","citation_count":9,"is_preprint":false},{"pmid":"34602532","id":"PMC_34602532","title":"MZF1 alleviates oxidative stress and apoptosis induced by rotenone in SH-SY5Y cells by promoting RBM3 transcription.","date":"2021","source":"The Journal of toxicological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34602532","citation_count":8,"is_preprint":false},{"pmid":"25065746","id":"PMC_25065746","title":"The glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH) is regulated by myeloid zinc finger 1 (MZF-1) and is induced by calcitriol.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25065746","citation_count":8,"is_preprint":false},{"pmid":"25899830","id":"PMC_25899830","title":"Myeloid Zinc Finger 1 (MZF-1) Regulates Expression of the CCN2/CTGF and CCN3/NOV Genes in the Hematopoietic Compartment.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25899830","citation_count":7,"is_preprint":false},{"pmid":"22559731","id":"PMC_22559731","title":"Expression of protein kinase Cα and the MZF-1 and elk-1 transcription factors in human bladder transitional cell carcinoma cells.","date":"2012","source":"The Chinese journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22559731","citation_count":7,"is_preprint":false},{"pmid":"38373662","id":"PMC_38373662","title":"Amelioration of nitroglycerin-induced migraine in mice via Wuzhuyu decoction: Inhibition of the MZF1/PGK1 pathway and activation of NRF2 antioxidant response.","date":"2024","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38373662","citation_count":6,"is_preprint":false},{"pmid":"35740998","id":"PMC_35740998","title":"Axl Expression in Renal Mesangial Cells Is Regulated by Sp1, Ap1, MZF1, and Ep300, and the IL-6/miR-34a Pathway.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35740998","citation_count":6,"is_preprint":false},{"pmid":"32449233","id":"PMC_32449233","title":"Cigarette smoke modulates binding of the transcription factor MZF1 to the VEGF promoter and regulates VEGF expression in dependence of genetic variation SNP 405.","date":"2020","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32449233","citation_count":6,"is_preprint":false},{"pmid":"35669102","id":"PMC_35669102","title":"MZF1 Transcriptionally Activated MicroRNA-328-3p Suppresses the Malignancy of Stomach Adenocarcinoma via Inhibiting CD44.","date":"2022","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/35669102","citation_count":6,"is_preprint":false},{"pmid":"39224032","id":"PMC_39224032","title":"MitoAMPK inhibits the Warburg effect by MZF1-SIRT6 with glycosis related genes in NSCLC.","date":"2024","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39224032","citation_count":5,"is_preprint":false},{"pmid":"23241556","id":"PMC_23241556","title":"Haplotype of single nucleotide polymorphisms in exon 6 of the MZF-1 gene and Alzheimer's disease.","date":"2013","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/23241556","citation_count":4,"is_preprint":false},{"pmid":"39133152","id":"PMC_39133152","title":"Solamargine acts as an antiviral by interacting to MZF1 and targeting the core promoter of the hepatitis B virus gene.","date":"2024","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/39133152","citation_count":2,"is_preprint":false},{"pmid":"39954358","id":"PMC_39954358","title":"Discovery of myeloid zinc finger (MZF) 1 nuclear bodies.","date":"2025","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39954358","citation_count":1,"is_preprint":false},{"pmid":"40961095","id":"PMC_40961095","title":"PRAME-AS lncRNA, regulated by MZF1, modulates PRAME expression and cell stemness.","date":"2025","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/40961095","citation_count":1,"is_preprint":false},{"pmid":"41003915","id":"PMC_41003915","title":"FTO-Mediated m6A Demethylation of MZF1 Regulates DECR1 to Promote Fatty Acid Oxidation and Exacerbate Myocardial Ischemia/Reperfusion Injury : FTO-Mediated m6A Demethylation of MZF1 Enhances Fatty Acid Oxidation and Aggravates Myocardial I/R Injury.","date":"2025","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41003915","citation_count":1,"is_preprint":false},{"pmid":"41343127","id":"PMC_41343127","title":"MZF1-AS1/NSUN2 promotes the peritoneal metastasis of gastric cancer by enhancing the stability of RAB13 mRNA.","date":"2025","source":"Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association","url":"https://pubmed.ncbi.nlm.nih.gov/41343127","citation_count":0,"is_preprint":false},{"pmid":"41201047","id":"PMC_41201047","title":"MicroRNA‑199a‑3p suppresses non‑small cell lung cancer progression by targeting FTO to enhance m6A‑mediated downregulation of MZF1 and its transcriptional activation of CLDND1.","date":"2025","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/41201047","citation_count":0,"is_preprint":false},{"pmid":"31934032","id":"PMC_31934032","title":"Regulation of expression of MLAA-34 gene through transcriptional factors E2F1 and MZF-1.","date":"2019","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31934032","citation_count":0,"is_preprint":false},{"pmid":"33352376","id":"PMC_33352376","title":"RETRACTED: MZF1 regulates α-globin gene transcription via long-range interactions in erythroid differentiation.","date":"2020","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/33352376","citation_count":0,"is_preprint":false},{"pmid":"31607299","id":"PMC_31607299","title":"[Effects of Transcription Factor MZF-1 on Transcriptive Regulation of Acute Monocytic Leukemia-related Gene MLAA-34].","date":"2019","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/31607299","citation_count":0,"is_preprint":false},{"pmid":"42249105","id":"PMC_42249105","title":"ALYREF stabilizes MZF1 via m5C modification to exacerbate cardiac remodeling and atrial fibrillation in heart failure.","date":"2026","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/42249105","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41661,"output_tokens":13110,"usd":0.160817,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":24575,"output_tokens":5030,"usd":0.124313,"stage2_stop_reason":"end_turn"},"total_usd":0.28513,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"MZF1 contains two independent DNA-binding domains (zinc fingers 1–4 and zinc fingers 5–13), each of which binds distinct but G-rich consensus sequences (1–4: 5'-AGTGGGGA-3'; 5–13: 5'-CGGGnGAGGGGGAA-3') as determined by affinity selection from degenerate oligonucleotide libraries followed by gel-shift assays with purified recombinant protein.\",\n      \"method\": \"Recombinant protein purification, SELEX (gel shift + PCR amplification), electrophoretic mobility shift assay (EMSA)\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified recombinant domains, SELEX-based site selection, independently validated by EMSA; foundational mechanistic paper replicated broadly\",\n      \"pmids\": [\"8114711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"MZF1 functions as a bifunctional transcriptional regulator: it represses transcription in non-hematopoietic cell lines (NIH 3T3, 293) and activates transcription in hematopoietic cell lines (K562, Jurkat) when fused to the GAL4 DNA-binding domain, and it directly binds MZF1 consensus sites in the CD34 promoter to regulate CD34 expression in a cell-type-specific manner.\",\n      \"method\": \"GAL4 fusion co-transfection/CAT reporter assay, luciferase reporter assay, EMSA with recombinant MZF1 on CD34 promoter oligonucleotides, site-directed mutation of MZF1 binding sites\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (reporter assay, EMSA, mutagenesis) in one study; replicated in subsequent work\",\n      \"pmids\": [\"7579328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Constitutive MZF1 overexpression in embryonic stem cells inhibits hematopoietic commitment and erythromyeloid colony formation, and suppresses CD34 and c-myb promoter activity by directly binding MZF1 consensus sites in their 5'-flanking regions.\",\n      \"method\": \"Retroviral/constitutive transfection into embryonic stem cells, CAT reporter assay, EMSA with recombinant MZF1 on CD34 and c-myb promoters\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — combined in vitro binding assay, promoter reporter, and functional ES cell differentiation readout; replicated across multiple constructs\",\n      \"pmids\": [\"7565760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Retroviral overexpression of MZF1 in NIH 3T3 fibroblasts causes loss of contact inhibition, loss of substrate dependence, accelerated cell cycling, and aggressive tumor formation in athymic mice, demonstrating oncogenic activity when MZF1 is aberrantly expressed.\",\n      \"method\": \"Retroviral transduction of NIH 3T3 cells, soft-agar/anchorage-independence assay, xenograft tumor formation in athymic mice\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean gain-of-function with multiple cellular readouts plus in vivo tumor assay; replicated in concept by subsequent studies\",\n      \"pmids\": [\"7627970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Retroviral overexpression of MZF1 in IL-3-dependent FDCP.1 cells inhibits apoptosis upon IL-3 withdrawal and confers tumorigenic potential (tumor formation in congenic mice), indicating MZF1 promotes cell survival.\",\n      \"method\": \"Retroviral transduction, apoptosis assay upon cytokine withdrawal, syngeneic tumor formation assay\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean gain-of-function in two functional assays (apoptosis and in vivo tumor formation), single lab\",\n      \"pmids\": [\"8667641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"MZF1 overexpression in HL-60 cells delays retinoic acid-induced differentiation and apoptosis and is associated with sustained Bcl-2 expression, suggesting MZF1 promotes cell proliferation and survival partly through Bcl-2.\",\n      \"method\": \"Retroviral transduction of HL-60 cells, cell-cycle analysis, morphologic differentiation scoring, TUNEL/DNA fragmentation assay, Western blot for Bcl-2, surface marker analysis\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal readouts in a defined cellular model, single lab\",\n      \"pmids\": [\"9593266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The SCAN box (LeR domain) present in the MZF1B isoform mediates protein–protein interactions: it is required for heterodimerization with the novel SCAN-related protein RAZ1 (identified by bone marrow cDNA library screen) and for MZF1B homodimerization, as demonstrated by co-immunoprecipitation and yeast two-hybrid analyses.\",\n      \"method\": \"Bone marrow cDNA library two-hybrid screen, co-immunoprecipitation, yeast two-hybrid with truncation constructs, in vitro self-association assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reciprocal co-IP plus yeast two-hybrid plus domain-mapping truncations; multiple orthogonal methods in one study\",\n      \"pmids\": [\"10777584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Targeted inactivation of Mzf1 in mice produces lethal myeloid neoplasias (chloroma-like infiltrations of the liver) and markedly increases autonomous hematopoietic progenitor proliferation and long-term hematopoiesis, establishing Mzf1 as a tumor/growth suppressor in the hematopoietic compartment.\",\n      \"method\": \"Gene targeting (Mzf1 knockout mice), histopathology, hematopoietic colony assays, long-term culture-initiating cell assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic knockout with defined in vivo and ex vivo phenotypic readouts; foundational study\",\n      \"pmids\": [\"11445537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MZF1 binds the GA-rich core of the human N-cadherin promoter (EMSA with osteoblast nuclear extracts, competition and supershift) and, together with Sp1, activates N-cadherin transcription in osteoblasts; Sp1 and MZF1 overexpression increases N-cadherin mRNA and protein.\",\n      \"method\": \"EMSA (including competition and supershift), deletion/mutation promoter-reporter analysis, co-transfection overexpression, RT-PCR\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA with supershift, promoter-reporter with mutation, and expression analysis, single lab\",\n      \"pmids\": [\"15541732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"NF-Y bound at CCAAT motifs in the ERV-9 LTR enhancer recruits MZF1 (and GATA-2) through protein–protein interactions to assemble an active enhancer complex (NF-Y/MZF1/GATA-2); NF-Y binding stabilizes MZF1 binding to neighboring GTGGGGA sites; mutation of the CCAAT motif abolishes enhancer activity and silences downstream gene transcription.\",\n      \"method\": \"EMSA, protein–protein interaction binding hierarchy assays (pull-down), chromatin analysis (DNase I sensitivity), stable plasmid integration reporter assay with site-directed mutations in K562 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple binding assays plus functional reporter with mutagenesis, single lab\",\n      \"pmids\": [\"16105833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MZF1 binds PKCα promoter elements in hepatocellular carcinoma cells, and antisense MZF1 oligonucleotides reduce PKCα mRNA, DNA-binding activity at the PKCα promoter, and decrease cell proliferation, migration, and invasion, placing MZF1 upstream of PKCα expression.\",\n      \"method\": \"Antisense oligonucleotide knockdown, RT-PCR, EMSA (DNA binding to PKCα promoter), cell proliferation/migration/invasion assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — loss-of-function with multiple cellular phenotype readouts plus EMSA, single lab\",\n      \"pmids\": [\"16297876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MZF-1 interacts with LDOC1 (a leucine-zipper protein) and enhances LDOC1-induced apoptosis; LDOC1 overexpression causes phosphatidylserine externalization and mitochondrial membrane potential loss leading to caspase-3-dependent and independent apoptosis.\",\n      \"method\": \"Co-immunoprecipitation (identification of MZF-1/LDOC1 interaction), overexpression assays, flow cytometry (apoptosis), mitochondrial membrane potential assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP interaction plus functional overexpression assays, single lab\",\n      \"pmids\": [\"15670815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The MZF1 SCAN domain forms a domain-swapped homodimer (Kd ~600 nM) determined by NMR spectroscopy, with the dimer interface centered on helix 3 of each monomer; GST pull-down confirmed self-association; this structure provides the molecular basis for SCAN-domain-mediated protein–protein interactions in this subfamily of zinc-finger transcription factors.\",\n      \"method\": \"NMR structure determination, GST pull-down self-association assay, tryptophan fluorescence polarization (Kd measurement), comprehensive sequence analysis\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR structure with functional validation (pull-down, Kd measurement) in single rigorous study\",\n      \"pmids\": [\"16950398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MZF1 represses ERCC1 promoter transcription: MZF1 N-terminal zinc fingers bind a MZF1-like site in the ERCC1 promoter (EMSA), MZF1 overexpression represses ERCC1 promoter-CAT activity, and cisplatin treatment decreases MZF1 mRNA, suggesting MZF1 normally represses ERCC1 and its loss upon cisplatin exposure allows ERCC1 upregulation.\",\n      \"method\": \"EMSA with MZF1 ZN1-4 consensus oligonucleotides, CAT reporter co-transfection assay, qPCR\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA plus reporter assay with overexpression, single lab\",\n      \"pmids\": [\"16426580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MZF1 and Sp1/Sp3 bind the proximal PADI1 promoter in vivo (ChIP assay), and siRNA knockdown of MZF1 reduces PADI1 expression in keratinocytes; mutation of MZF1- or Sp1-binding sites markedly reduces PADI1 promoter activity, establishing MZF1 as a direct transcriptional activator of PADI1.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), luciferase reporter assay with deletion/mutation constructs, siRNA knockdown, qRT-PCR\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (ChIP, reporter mutagenesis, siRNA KD) in one study\",\n      \"pmids\": [\"17851584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MZF-1 binds a cis-element at -785/-745 in the FGF-2 promoter (identified by promoter deletion screening) and mediates apomorphine-stimulated FGF-2 transcription in astrocytes; MZF-1 plasmid overexpression increases FGF-2 protein in HeLa cells and primary astrocytes, while MZF-1-specific siRNA reduces FGF-2 promoter activity.\",\n      \"method\": \"Promoter deletion/reporter assay, MZF-1 overexpression and siRNA knockdown, FGF-2 protein measurement\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with reporter and protein readouts, single lab\",\n      \"pmids\": [\"19196427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MZF1 binds the cis-element 'TGGGGA' in the p55PIK (PI3K regulatory subunit) promoter (ChIP assay), and MZF1 overexpression increases while MZF1 silencing decreases p55PIK promoter activity, p55PIK expression, and colorectal cancer cell proliferation.\",\n      \"method\": \"ChIP assay, promoter-luciferase reporter assay, MZF1 overexpression and siRNA knockdown, cell proliferation assay\",\n      \"journal\": \"BioMed research international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter plus bidirectional modulation, single lab\",\n      \"pmids\": [\"23509792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MZF1 acts as a transcriptional activator of the ferroportin (FPN) gene; reduced MZF1 expression in prostate tumors leads to decreased FPN, increased intracellular iron retention, and enhanced tumor cell growth. AP4 and c-Myb jointly activate MZF1 transcription, while miR-492 directly binds the MZF1 3'UTR to suppress MZF1 expression.\",\n      \"method\": \"MZF1 knockdown/overexpression, FPN promoter-reporter assay, iron assay, cell growth assay, miR-492 3'UTR reporter assay, quantitative RT-PCR/Western blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional modulation with multiple functional readouts, single lab\",\n      \"pmids\": [\"25284586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Tumor-derived osteopontin (OPN) induces integrin-dependent MZF1 expression in mesenchymal stem cells, which is required for TGF-β1 production and MSC-to-cancer-associated-fibroblast (CAF) transformation; MZF1 knockdown abolishes OPN-induced TGF-β1 expression and CAF phenotype acquisition.\",\n      \"method\": \"In vitro MSC/cancer cell co-culture, OPN treatment, siRNA knockdown of MZF1, TGF-β1 ELISA, CAF marker analysis, xenotransplant mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined molecular pathway and in vivo validation, single lab\",\n      \"pmids\": [\"25531323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Wild-type LKB1 loss increases MZF1 expression, and MZF1 directly transcriptionally upregulates c-MYC; the MZF1/c-MYC axis drives soft-agar growth, migration and invasion in lung adenocarcinoma cells; MYC inhibitors suppress LKB1-loss-induced invasiveness.\",\n      \"method\": \"LKB1 knockdown/overexpression, MZF1 promoter-reporter assay, ChIP, soft-agar colony formation, migration/invasion assays, MYC inhibitor treatment\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter plus functional cellular assays with pharmacologic validation, single lab\",\n      \"pmids\": [\"24793789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MZF1 binds and transactivates the FOXM1 promoter via the MZF1/NKX2-1 axis in HPV E6-positive cancer cells; E6-mediated upregulation of NKX2-1 induces MZF1, which drives FOXM1 expression and consequent Wnt/β-catenin activation, soft-agar growth, invasiveness, and stemness.\",\n      \"method\": \"siRNA knockdown, luciferase reporter assay, nude mouse metastasis model, FOXM1 inhibitor treatment, ChIP\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter, ChIP, and in vivo data, single lab\",\n      \"pmids\": [\"25425970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MZF1 and Ik-1 bind specific sites in the IGF-IR gene promoter (ChIP assay), suppress IGF-IR promoter activity (luciferase assay), and forced MZF1 expression in NPM-ALK+ T-cell lymphoma cells decreases IGF-IR mRNA and protein, phospho-IGF-IR, IRS-1, AKT and NPM-ALK phosphorylation, and reduces cell viability, proliferation, migration, and anchorage-independent growth.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, forced MZF1 expression, Western blot for downstream signaling, cell viability/proliferation/migration/colony assays\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, reporter, and multiple functional readouts, single lab\",\n      \"pmids\": [\"25884514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MZF1 directly binds and activates the CTGF (CCN2) and NOV (CCN3) gene promoters in hematopoietic cells; calcitriol and vitamin A upregulate MZF1, which in turn induces CTGF and NOV expression; MZF1 shRNA knockdown reduces CTGF and NOV levels.\",\n      \"method\": \"MZF1-promoter interaction assay, MZF1 overexpression/knockdown, RT-PCR/Western blot, calcitriol/vitamin A stimulation\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — bidirectional modulation with protein-promoter interaction assays, single lab\",\n      \"pmids\": [\"25899830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MZF1 directly binds the SMAD4 core promoter and stimulates SMAD4 transcriptional activity; MZF1 expression promotes SMAD4 levels and suppresses migration of gastric adenocarcinoma cells.\",\n      \"method\": \"Promoter-reporter assay, EMSA, MZF1 overexpression, migration assay\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — EMSA, reporter, and functional migration readout, single lab\",\n      \"pmids\": [\"27922669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MZF1 directly binds the GAPDH promoter and upregulation of MZF1 by calcitriol induces GAPDH expression in HS-5 stromal fibroblasts; shRNA knockdown of MZF1 reduces GAPDH expression.\",\n      \"method\": \"Promoter binding assay, MZF1 knockdown (shRNA), calcitriol stimulation, Western blot/RT-PCR\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — bidirectional modulation with promoter binding evidence, single lab\",\n      \"pmids\": [\"25065746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MZF1 forms a direct physical complex with Elk-1: Elk-1 binds the N-terminal acidic region of MZF1, MZF1 binds the C-terminal region of Elk-1; the MZF1/Elk-1 heterodimer binds the PKCα promoter to activate PKCα transcription in hepatocellular carcinoma cells; disruption of MZF1/Elk-1 dimerization reduces PKCα expression, and cell proliferation, migration, invasion, and tumorigenicity.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, Re-ChIP, luciferase reporter assay with DNA-binding-deficient mutants, cell functional assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reciprocal Co-IP, ChIP/Re-ChIP, domain-specific mutants, and multiple functional readouts in one study\",\n      \"pmids\": [\"26010542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The acidic domain (residues 60–72) of MZF1 and the heparin-binding domain (residues 145–157) of Elk-1 constitute the heterodimerization interface; peptides from either domain block MZF1/Elk-1 complex formation, reduce PKCα promoter binding (DNA-binding activity), and decrease PKCα expression, cell migration, tumorigenicity, and EMT potential in triple-negative breast cancer cells.\",\n      \"method\": \"Peptide competition assay, co-immunoprecipitation, ChIP, luciferase reporter assay, cell migration/invasion/tumorigenicity assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-mapping peptide competition with Co-IP, ChIP, and multiple functional readouts; single lab building on prior study\",\n      \"pmids\": [\"27542222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The MZF1 SCAN domain adopts a conformational ensemble (validated by NMR experimental data) that mediates protein–protein interactions; cancer-associated missense substitutions in the SCAN domain perturb its interaction network as revealed by integrated proteomics, RNAseq, and molecular dynamics simulations.\",\n      \"method\": \"NMR cross-validation, molecular dynamics simulations, high-throughput proteomics and RNASeq data analysis, computational network analysis\",\n      \"journal\": \"Frontiers in molecular biosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — NMR-validated structural ensemble but primarily computational; no direct mutagenesis functional validation in cells\",\n      \"pmids\": [\"28018905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MZF1 directly binds MZF1 consensus sites within the first intron (CpG-rich region) of the PRAME gene and activates PRAME transcription; DNA demethylation (5-azaC treatment) enhances MZF1 binding and further increases PRAME expression; MZF1, like PRAME, promotes colony-forming ability in melanoma cells.\",\n      \"method\": \"ChIP, luciferase reporter assay, 5-azaC treatment, EMSA, MZF1 overexpression, colony formation assay\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, reporter, and functional assay, single lab\",\n      \"pmids\": [\"28634046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TGF-β1-activated ERK1/2 signaling induces MZF1, which binds the CK17 promoter and activates CK17 transcription; CK17 (not EMT markers) mediates acquisition of cancer stem cell properties and lymphatic metastasis in cervical cancer; ERK1/2 inhibitors block TGF-β1-induced MZF1 and CK17 upregulation.\",\n      \"method\": \"Computational binding site prediction validated by ChIP, promoter-reporter assay, ERK1/2 inhibitor treatment, siRNA knockdown, in vivo lymphatic metastasis model\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, reporter, pharmacologic inhibition, and in vivo data, single lab\",\n      \"pmids\": [\"28703907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FTO (m6A demethylase) enhances MZF1 mRNA stability by reducing m6A methylation of MZF1 mRNA; FTO knockdown reduces MZF1 expression (whereas catalytic mutant FTO does not rescue), and MZF1 mediates FTO's pro-tumorigenic functions in lung squamous cell carcinoma.\",\n      \"method\": \"FTO knockdown/overexpression (WT and catalytic mutant), RT-PCR/Western blot for MZF1, mRNA stability assay, cell proliferation/invasion/apoptosis assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — catalytic mutant rescue experiment distinguishes enzymatic vs. scaffolding role; functional readouts; single lab\",\n      \"pmids\": [\"29842885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CHIP/STUB1 ubiquitin ligase negatively regulates MZF1 DNA-binding activity in the nucleus; loss of nuclear CHIP in breast cancer unleashes MZF1-driven cathepsin B/L (CTSB/L) expression, promoting tumor cell invasion and matrix degradation; ectopic CHIP expression suppresses MZF1 activity and in vivo xenograft growth.\",\n      \"method\": \"Unbiased nuclear transcription factor screen, ectopic CHIP expression, CTSB/L expression analysis, in vitro invasion/matrix degradation assays, in vivo xenograft assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with in vivo validation and functional pathway delineation, single lab\",\n      \"pmids\": [\"29510992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CK2 directly phosphorylates MZF1 at serine 27, which stabilizes MZF1 protein; stabilized MZF1 binds the N-cadherin promoter (ChIP) and activates N-cadherin transcription; MZF1 knockdown downregulates N-cadherin, reverts cancer cells from mesenchymal to epithelial morphology, and reduces motility and invasiveness.\",\n      \"method\": \"N-cadherin promoter analysis, ChIP, co-immunoprecipitation (MZF1–CK2 interaction), phosphorylation assay (serine 27), MZF1 knockdown, morphology/motility/invasion assays\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — identified writer kinase (CK2), specific phosphorylation site (S27), ChIP, and multiple orthogonal functional assays in one study\",\n      \"pmids\": [\"29540671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The FBXO28–TRAF6 E3 ligase complex binds ERK5, promotes ERK5 K63-ubiquitination and phosphorylation; activated ERK5 drives MZF1 expression, and MZF1 directly binds the RGC-32 promoter to upregulate RGC-32, ultimately mediating sublytic C5b-9-induced mesangial cell proliferation and ECM expansion in glomerulonephritis.\",\n      \"method\": \"Western blot, co-immunoprecipitation (FBXO28–TRAF6–ERK5 complex), ubiquitination assay, MZF1 promoter-binding analysis, siRNA knockdown of each component, in vivo Thy-1 nephritis rat model\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multi-step pathway defined by Co-IP, ubiquitination assay, and siRNA knockdowns with in vivo validation, single lab\",\n      \"pmids\": [\"31184423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MZF1 binds the TRPV1 promoter in dorsal root ganglion (DRG) neurons and regulates TRPV1 expression; DRG microinjection of MZF1 overexpression virus increases TRPV1 and induces mechanical allodynia/thermal hyperalgesia, while MZF1 siRNA reduces CCI-induced TRPV1 upregulation and alleviates neuropathic pain behaviors.\",\n      \"method\": \"DRG microinjection of rAAV5-MZF1 or MZF1 siRNA, behavioral pain assays (PWT, PWL), Western blot/immunofluorescence for TRPV1\",\n      \"journal\": \"Neural plasticity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional modulation in vivo with specific behavioral and molecular readouts, single lab\",\n      \"pmids\": [\"31582966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MZF1 promotes HK2 and PGK1 expression to drive aerobic glycolysis in neuroblastoma. YY1 transcription factor transactivates MZF1 transcription; a 21-amino-acid peptide (MZF1-uPEP) encoded by the upstream ORF of MZF1 binds the zinc finger domain of YY1, represses YY1 transactivation, and thereby reduces MZF1, HK2, and PGK1 expression and inhibits glycolysis and tumor progression.\",\n      \"method\": \"Dual-luciferase assay, ChIP, co-immunoprecipitation, mass spectrometry, peptide pull-down assay, seahorse extracellular flux, soft agar, Matrigel invasion, nude mice xenograft\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (Co-IP, mass spec, pulldown, ChIP, reporter, in vivo) in one study; well-validated MZF1-uPEP mechanism\",\n      \"pmids\": [\"32042322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MZF1 acts as a transcription factor for ALDH18A1 and PYCR1, promoting proline synthesis in neuroblastoma; MZF1-AS1 lncRNA binds PARP1 to facilitate its interaction with E2F1, resulting in E2F1 transactivation of MZF1 and downstream oncogenic genes; a small peptide blocking MZF1-AS1–PARP1 interaction suppresses proline synthesis and NB progression.\",\n      \"method\": \"Dual-luciferase assay, ChIP, co-immunoprecipitation, peptide/RIP pulldown, amino acid profiling, lentiviral MZF1-AS1 shRNA, in vivo tumor assays\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods; note that MZF1-AS1 itself is a non-protein lncRNA but the MZF1 protein mechanistic findings are captured here; single lab\",\n      \"pmids\": [\"31592410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MZF1 binds the Mtor promoter at the TGGGGA cis-element near the transcription start site and down-regulates Mtor expression; a BALB mouse-specific T at the -6 position creates the consensus MZF1 binding site, explaining strain-specific differences in Mtor promoter activity; MZF1 overexpression reduces and Mzf1 knockdown increases Mtor expression in fibroblasts and plasmacytoma cells.\",\n      \"method\": \"EMSA, DNA pulldown, ChIP-PCR, luciferase reporter assay with allelic variants, MZF1 overexpression/knockdown in cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — EMSA, DNA pulldown, ChIP, reporter, and bidirectional modulation, multiple orthogonal methods in one study\",\n      \"pmids\": [\"31548308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Linc01060 (a lncRNA from hypoxic glioma stem cell exosomes) directly interacts with MZF1 protein and enhances its stability; Linc01060 facilitates nuclear translocation of MZF1 and promotes MZF1-mediated c-Myc transcriptional activity; c-Myc then increases HIF1α accumulation post-transcriptionally, which feeds back to activate Linc01060 transcription.\",\n      \"method\": \"RNA immunoprecipitation (RIP), co-immunoprecipitation, nuclear fractionation, dual-luciferase, ChIP, overexpression/knockdown assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIP/Co-IP and nuclear fractionation with reporter and ChIP; single lab; note this is about the MZF1 protein mechanism\",\n      \"pmids\": [\"33158815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MZF1 recruits chromodomain helicase DNA binding protein 7 (CHD7) to the p16INK4A (CDKN2A) promoter to mediate oncogenic Ras-induced p16INK4A transcription and cellular senescence in primary human cells; MZF1 expression is induced by oncogenic Ras through the c-Jun and Ets1 transcription factors activated by the Ras-Raf-1-MEK-ERK signaling cascade.\",\n      \"method\": \"ChIP, co-immunoprecipitation (MZF1–CHD7), MZF1 knockdown/overexpression, p16INK4A promoter-reporter assay, senescence assays (SA-β-gal), oncogenic Ras expression, pathway inhibitor treatments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — Co-IP identifying CHD7 as MZF1 cofactor, ChIP showing recruitment to p16INK4A promoter, pathway epistasis with inhibitors, and functional senescence readout; multiple orthogonal methods\",\n      \"pmids\": [\"34773072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GSK3β mediates ubiquitination and degradation of the m6A demethylase FTO, thereby increasing m6A methylation of MZF1 mRNA and reducing MZF1 expression, which in turn decreases c-Myc expression and suppresses colorectal cancer cell proliferation; overexpressing c-Myc reverses GSK3β-mediated tumor suppression in vivo.\",\n      \"method\": \"Ubiquitination assay, m6A MeRIP, protein stability assay, transfection of overexpression/interference plasmids, in vivo tumor model\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay plus m6A profiling plus in vivo rescue, single lab\",\n      \"pmids\": [\"33533172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Irradiation increases MZF1 expression in alveolar epithelial cells; MZF1 binds the miR-541-5p primary precursor promoter and represses miR-541-5p transcription; reduced miR-541-5p releases its target Slug, promoting EMT and radiation-induced pulmonary fibrosis; ectopic miR-541-5p expression mitigates RIPF in mice.\",\n      \"method\": \"Luciferase reporter assay, ChIP (MZF1 binding to miR-541-5p promoter), overexpression/knockdown of MZF1 and miR-541-5p, in vivo RIPF mouse model, EMT marker analysis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, reporter, and in vivo data, single lab\",\n      \"pmids\": [\"34768749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MZF1 cooperates with SETD8 (lysine methyltransferase) to regulate WNT5A promoter transcription in glomerular endothelial cells: MZF1 and SETD8 co-occupy the WNT5A promoter (ChIP), physically interact (Co-IP), and under high-glucose conditions MZF1 and SETD8 mutually inhibit each other while together activating WNT5A, leading to NF-κB pathway activation and endothelial inflammation.\",\n      \"method\": \"ChIP, co-immunoprecipitation, dual-luciferase assay, siRNA/overexpression of MZF1 and SETD8, in vivo DN rat model, Western blot for p-p65/inflammatory markers\",\n      \"journal\": \"Cellular & molecular biology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ChIP, reporter, bidirectional modulation, and in vivo model; single lab\",\n      \"pmids\": [\"35350980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MZF1 binds the SIRT6 promoter and regulates SIRT6 expression; SIRT6 inhibits the Warburg effect by regulating glycolysis genes (SLC2A2, SLC2A4, PKM2); the MZF1-SIRT6 complex is demonstrated by ChIP-qPCR; mitoAMPK acts upstream of the MZF1-SIRT6 axis.\",\n      \"method\": \"ChIP-qPCR (MZF1–SIRT6 promoter interaction), Western blot, qPCR, CCK-8, immunohistochemistry, glycolysis gene expression analysis\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single ChIP-qPCR experiment with limited mechanistic follow-up, single lab\",\n      \"pmids\": [\"39224032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MZF1 binds and represses the SLC1A5 (ASCT2) promoter; the lncRNA SLC1A5-AS directly binds MZF1 protein (biotin-labeled probe pulldown), sequestering it from the promoter and thereby de-repressing ASCT2 to enhance glutamine uptake and HCC progression.\",\n      \"method\": \"Biotin-labeled RNA probe pulldown/Western blot (SLC1A5-AS–MZF1 interaction), ChIP, dual-luciferase reporter assay, overexpression/knockdown, glutamine uptake assay, in vitro and in vivo functional assays\",\n      \"journal\": \"Discovery medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA pulldown, ChIP, and reporter with functional readouts; single lab; note the lncRNA mechanism is supporting context, the MZF1 protein binding/repression is directly demonstrated\",\n      \"pmids\": [\"38058065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"UHRF1/DNMT1-mediated hypermethylation of an intragenic CpG island in PRSS3 prevents MZF1 binding to regulate PRSS3 isoform transcription; when iCpGI is demethylated (by diallyl trisulfide + 5-azaC), MZF1 specifically binds to upregulate tumor-suppressive PRSS3-V3 expression.\",\n      \"method\": \"DNMT1/UHRF1 complex assay, bisulfite sequencing, MZF1 ChIP on iCpGI, luciferase reporter assay, pharmacologic demethylation, isoform-specific RT-PCR\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, reporter, and epigenetic modulation with isoform-specific readouts; single lab\",\n      \"pmids\": [\"37250150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MZF1 accelerates PD-L1 ubiquitination by binding to the CDK4 activation site; CDK4 directly binds MZF1 (co-immunoprecipitation) leading to increased MZF1 expression; ectopic MZF1 expression impairs T-cell recruitment into tumors and confers resistance to anti-PD-L1 immunotherapy in hepatocellular carcinoma.\",\n      \"method\": \"Co-immunoprecipitation (CDK4–MZF1 complex), ubiquitination assay, proteome analysis, protein degradation assays, orthotopic and hydrodynamic HCC mouse models, T-cell infiltration analysis\",\n      \"journal\": \"JHEP reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination assay, and in vivo models with immune readout; single lab\",\n      \"pmids\": [\"38074509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MZF1 is the transcription factor that activates CLDND1 expression; the miR-199a-3p/FTO/MZF1 axis regulates NSCLC: miR-199a-3p suppresses FTO, enhancing m6A modification of MZF1 mRNA (confirmed by MeRIP and CLIP) and reducing MZF1, which decreases CLDND1 and inhibits NSCLC cell malignancy.\",\n      \"method\": \"Methylated RNA immunoprecipitation (MeRIP), CLIP (photoactivatable ribonucleoside-enhanced CLIP for FTO–MZF1 mRNA binding), dual-luciferase assay (miR-199a-3p targeting FTO; MZF1 activating CLDND1), MZF1 knockdown, cell proliferation/invasion/migration/apoptosis assays\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — MeRIP and CLIP for post-transcriptional m6A mechanism, reporter for CLDND1 transcriptional activation, multiple orthogonal methods; single lab\",\n      \"pmids\": [\"41201047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MZF1 forms discrete intranuclear oligomeric structures termed MZF1 nuclear bodies (MZF1-NBs), distinct from but associated with PML-NBs; MZF1 is SUMOylated at SUMO1 in PC-3 cells, enabling interaction with SUMO-interaction motif (SIM)-containing proteins; interactome analysis of MZF1-NBs identified cofactors involved in stress response (TPR, UBAP2L), protein folding (CALR, ANKRD40), post-translational modification (TRIM33, CAMK2D, CAMK2G), and RNA binding (ALURBP, CPSF5).\",\n      \"method\": \"Live-cell imaging (nuclear body morphology), proteomic interactome analysis, co-immunoprecipitation, SUMO1 modification assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct subcellular localization and proteomics-based interactome, single lab, single study with limited functional validation\",\n      \"pmids\": [\"39954358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NSUN2-mediated m5C modification of MZF1 mRNA is required for its recognition and stabilization by the m5C reader protein ALYREF; ALYREF knockdown reduces MZF1 and HTRA1 expression, alleviates myocardial hypertrophy, fibrosis, and atrial fibrillation inducibility in an ISO-induced heart failure mouse model.\",\n      \"method\": \"MeRIP-qPCR for m5C on MZF1 mRNA, RIP-qPCR (ALYREF–MZF1 mRNA interaction), actinomycin D mRNA stability assay, ChIP (MZF1 on HTRA1 promoter), dual-luciferase reporter, in vivo HF mouse model with ALYREF knockdown\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — m5C MeRIP, RIP, mRNA stability assay, ChIP, and in vivo data; single lab\",\n      \"pmids\": [\"42249105\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MZF1 is a Krüppel-family C2H2 zinc finger transcription factor with two independent DNA-binding domains that recognize G-rich consensus sequences; it functions as a bifunctional regulator—activating transcription in hematopoietic cells and repressing it in non-hematopoietic contexts—and acts either as a tumor suppressor (driving p16INK4A/senescence, ferroportin-mediated iron egress) or oncogene (driving c-Myc, PKCα, cathepsin B/L, and glycolytic genes) depending on cellular context; its activity is post-translationally regulated by CK2-mediated phosphorylation at serine 27 (stabilization), CHIP ubiquitin-ligase-mediated repression, and SUMO1 modification, while its mRNA stability is controlled by FTO-mediated m6A demethylation and NSUN2/ALYREF-mediated m5C stabilization; its SCAN domain forms a domain-swapped homodimer and mediates heterodimerization with partners including RAZ1, Elk-1, CHD7, YY1, SETD8, and CDK4, enabling context-dependent transcriptional programs across hematopoiesis, cancer invasion/EMT, glycolysis, senescence, and neuropathic pain.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MZF1 (myeloid zinc finger 1) is a Krüppel-family C2H2 zinc finger transcription factor that uses two independent DNA-binding domains—zinc fingers 1–4 and 5–13, each recognizing a distinct G-rich consensus—to regulate target genes from G-rich promoter elements [#0]. It functions as a context-dependent bifunctional regulator, repressing transcription in non-hematopoietic cells while activating it in hematopoietic cells, and it directly controls hematopoietic differentiation genes including CD34 and c-myb [#1, #2]. Genetic loss of Mzf1 in mice causes lethal myeloid neoplasia and autonomous progenitor proliferation, establishing it as a hematopoietic growth/tumor suppressor, whereas aberrant overexpression confers anchorage-independent growth and tumorigenicity in fibroblasts and survival signaling in myeloid cells [#3, #7]. Across cancers MZF1 directly transactivates a broad set of pro-tumorigenic targets—c-MYC, PKCα, FOXM1, p55PIK, and cathepsin B/L—to drive proliferation, invasion, EMT, and matrix degradation [#19, #25, #20, #31], yet it also acts as a tumor suppressor by activating ferroportin and SMAD4 and by repressing IGF-IR, illustrating strict context dependence [#17, #23, #21]. Its protein–protein interactions are organized by an N-terminal SCAN domain that forms a domain-swapped homodimer and supports heterodimerization with partners such as RAZ1, and by a separate acidic region that mediates direct heterodimerization with Elk-1 to assemble DNA-binding transcription complexes on the PKCα promoter [#12, #6, #25]. MZF1 also nucleates cofactor complexes with CHD7 to drive oncogenic-Ras-induced p16INK4A transcription and senescence, and with SETD8 on the WNT5A promoter [#39, #42]. Its activity and abundance are tightly post-translationally controlled: CK2 phosphorylates MZF1 at serine 27 to stabilize it and promote N-cadherin-driven EMT, the CHIP/STUB1 ubiquitin ligase represses its nuclear DNA-binding activity, and SUMO1 modification organizes MZF1 into intranuclear nuclear bodies (MZF1-NBs) linked to a stress-response and RNA-binding interactome [#32, #31, #48]. MZF1 mRNA itself is a node of RNA modification control, being stabilized by FTO-mediated m6A demethylation and by NSUN2/ALYREF-mediated m5C reading [#30, #40, #49]. Beyond cancer, MZF1 transcriptionally regulates TRPV1 in dorsal root ganglion neurons to drive neuropathic pain and engages glycolytic and proline-synthesis programs (HK2, PGK1, ALDH18A1, PYCR1) in neuroblastoma, where a uORF-encoded micropeptide modulates its upstream activator YY1 [#34, #35, #36].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Defining the DNA-recognition logic of MZF1 was the first mechanistic question: the work established that MZF1 has two independent zinc-finger DNA-binding modules each recognizing a distinct G-rich consensus, explaining how one factor can engage diverse promoters.\",\n      \"evidence\": \"SELEX site selection and EMSA with purified recombinant zinc-finger domains\",\n      \"pmids\": [\"8114711\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish which target genes the two consensus motifs map to in vivo\", \"No structural model of finger-DNA contacts\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"These studies resolved whether MZF1 activates or represses, showing it is bifunctional in a cell-type-dependent manner and directly controls hematopoietic genes CD34 and c-myb, framing MZF1 as a regulator of myeloid differentiation.\",\n      \"evidence\": \"GAL4-fusion reporter assays, EMSA, promoter mutagenesis, and ES-cell differentiation readouts in hematopoietic vs non-hematopoietic lines\",\n      \"pmids\": [\"7579328\", \"7565760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of the activator-vs-repressor switch (cofactor identity) not defined\", \"Did not identify cell-type-specific partners driving the switch\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Gain-of-function experiments addressed whether dysregulated MZF1 is oncogenic, demonstrating that aberrant overexpression transforms fibroblasts and promotes tumor formation and that it blocks IL-3-withdrawal apoptosis, linking MZF1 to proliferation and survival.\",\n      \"evidence\": \"Retroviral overexpression with anchorage-independence, xenograft/syngeneic tumor formation, and cytokine-withdrawal apoptosis assays\",\n      \"pmids\": [\"7627970\", \"8667641\", \"9593266\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transforming target genes not identified in these models\", \"Survival mechanism beyond association with Bcl-2 not delineated\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"A definitive loss-of-function test asked whether endogenous Mzf1 restrains hematopoietic growth in vivo, showing knockout mice develop lethal myeloid neoplasia and autonomous progenitor proliferation—establishing MZF1 as a hematopoietic tumor/growth suppressor in apparent paradox with its oncogenic overexpression phenotypes.\",\n      \"evidence\": \"Mzf1 knockout mice with histopathology and hematopoietic colony/LTC-IC assays\",\n      \"pmids\": [\"11445537\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct target genes mediating the suppressor phenotype not identified\", \"Reconciliation of suppressor vs oncogene roles at molecular level unresolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"To explain how MZF1 forms higher-order complexes, the SCAN/LeR domain was identified as the protein-interaction module mediating homodimerization and heterodimerization with the SCAN-related partner RAZ1.\",\n      \"evidence\": \"Bone-marrow two-hybrid screen, co-IP, and yeast two-hybrid truncation mapping\",\n      \"pmids\": [\"10777584\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of RAZ1 heterodimerization on transcription not tested\", \"Full repertoire of SCAN partners unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Structural work answered how the SCAN domain mediates dimerization, revealing a domain-swapped homodimer with a helix-3 interface and a measurable affinity, providing the molecular basis for SCAN-mediated interactions.\",\n      \"evidence\": \"NMR structure determination, GST pull-down, and Kd measurement by fluorescence polarization\",\n      \"pmids\": [\"16950398\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of heterodimeric SCAN complexes not solved\", \"No structure of full-length MZF1 with DNA\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identification of direct promoter targets in non-hematopoietic contexts (N-cadherin, ERV-9 LTR, PKCα, ERCC1) and partners (NF-Y, GATA-2, Sp1, LDOC1) showed MZF1 assembles cell-type-specific enhancer complexes and can both activate and repress distinct targets.\",\n      \"evidence\": \"EMSA/supershift, promoter-reporter mutagenesis, antisense/co-transfection, and co-IP across osteoblast, K562, hepatoma, and apoptosis models\",\n      \"pmids\": [\"15541732\", \"16105833\", \"16297876\", \"16426580\", \"15670815\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether MZF1 directly recruits the named partners or co-occupies independently is often not separated\", \"In vivo relevance of individual targets to physiology not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"A large body of cancer studies mapped MZF1 into specific oncogenic and tumor-suppressive transcriptional circuits, defining context-dependent direct targets (c-MYC, FOXM1, p55PIK, ferroportin, SMAD4, IGF-IR, PRAME, CK17) and upstream activators (LKB1 loss, OPN/integrin, NKX2-1, TGF-β1/ERK).\",\n      \"evidence\": \"ChIP, promoter-reporter assays, bidirectional knockdown/overexpression, pharmacologic pathway inhibition, and xenograft/metastasis models across multiple tumor types\",\n      \"pmids\": [\"24793789\", \"25425970\", \"23509792\", \"25284586\", \"27922669\", \"25884514\", \"28634046\", \"28703907\", \"25531323\", \"25899830\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"What determines oncogene vs suppressor target selection in a given tissue is not resolved\", \"Most targets are demonstrated in a single lab/model\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A second mechanistic layer was opened by showing MZF1 is itself heavily post-translationally and post-transcriptionally regulated: CK2 phosphorylation at S27 stabilizes it, CHIP/STUB1 represses its nuclear DNA-binding, SUMO1 organizes it into MZF1 nuclear bodies, and m6A (FTO) and m5C (NSUN2/ALYREF) marks tune its mRNA stability.\",\n      \"evidence\": \"Phosphorylation/co-IP assays, ubiquitin-ligase functional screens, SUMOylation and live-cell imaging with interactome proteomics, and MeRIP/RIP/CLIP/mRNA-stability assays with in vivo models\",\n      \"pmids\": [\"29540671\", \"29510992\", \"48\", \"39954358\", \"29842885\", \"33533172\", \"41201047\", \"42249105\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional output of MZF1-NBs and SUMOylation not mechanistically tied to transcriptional programs\", \"How these inputs are integrated to set net MZF1 activity is undefined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Cofactor-based mechanisms clarified how MZF1 controls senescence and metabolic programs: it recruits CHD7 to the p16INK4A promoter to enact oncogenic-Ras senescence, cooperates with SETD8 on WNT5A, and drives glycolytic/proline-synthesis genes regulated by a uORF-encoded micropeptide acting on its activator YY1.\",\n      \"evidence\": \"Co-IP cofactor identification, ChIP, senescence assays, Seahorse/amino-acid profiling, peptide pull-down, and xenografts\",\n      \"pmids\": [\"34773072\", \"35350980\", \"32042322\", \"31592410\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of CHD7/SETD8 recruitment across other targets unknown\", \"How chromatin cofactor choice is governed is unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"MZF1 was shown to operate in non-cancer tissue contexts—neuropathic pain via TRPV1 in DRG neurons, glomerular inflammation/fibrosis via RGC-32 and WNT5A, mTOR regulation, and cardiac remodeling via HTRA1—broadening its physiological reach beyond hematopoiesis and tumors.\",\n      \"evidence\": \"DRG microinjection with behavioral assays, ChIP/reporter assays, EMSA/DNA pulldown for allelic Mtor sites, and in vivo nephritis, fibrosis, and heart-failure models\",\n      \"pmids\": [\"31582966\", \"31184423\", \"31548308\", \"42249105\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue-specific cofactors enabling these distinct programs not identified\", \"Most physiological roles rest on single studies\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The central unresolved question is what molecular determinant switches MZF1 between tumor-suppressor and oncogene roles and selects its activator vs repressor mode on a given promoter.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking partner identity, post-translational state, and target selection\", \"No genome-wide occupancy comparison across hematopoietic vs non-hematopoietic contexts in the corpus\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 2, 14, 25, 32, 37]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 2, 13, 37]},\n      {\"term_id\": \"GO:0003700\", \"supporting_discovery_ids\": [1, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [31, 48]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [48]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 2, 14, 25, 32, 37]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 7, 19, 31, 35]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [30, 40, 47, 49]}\n    ],\n    \"complexes\": [\n      \"MZF1 SCAN domain-swapped homodimer\",\n      \"MZF1/Elk-1 heterodimer\",\n      \"MZF1 nuclear bodies (MZF1-NBs)\"\n    ],\n    \"partners\": [\n      \"RAZ1\",\n      \"Elk-1\",\n      \"CHD7\",\n      \"SETD8\",\n      \"CDK4\",\n      \"CK2\",\n      \"STUB1\",\n      \"YY1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}